[
  {
    "id": 0,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 0,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:0"
  },
  {
    "id": 1,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 1,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:0"
  },
  {
    "id": 2,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 2,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:0"
  },
  {
    "id": 3,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 3,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:1"
  },
  {
    "id": 4,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 4,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:1"
  },
  {
    "id": 5,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 5,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:1"
  },
  {
    "id": 6,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 6,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:1"
  },
  {
    "id": 7,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 7,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:1"
  },
  {
    "id": 8,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 8,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:1"
  },
  {
    "id": 9,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 9,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:2"
  },
  {
    "id": 10,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 10,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:2"
  },
  {
    "id": 11,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 11,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:2"
  },
  {
    "id": 12,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 12,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:3"
  },
  {
    "id": 13,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 13,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:3"
  },
  {
    "id": 14,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 14,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:3"
  },
  {
    "id": 15,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.akeega"
    ],
    "proposition_id": 15,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.akeega:0"
  },
  {
    "id": 16,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.akeega"
    ],
    "proposition_id": 16,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.akeega:0"
  },
  {
    "id": 17,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.akeega"
    ],
    "proposition_id": 17,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.akeega:0"
  },
  {
    "id": 18,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.akeega"
    ],
    "proposition_id": 18,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.akeega:0"
  },
  {
    "id": 19,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to adagrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least one prior systemic therapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR), and that continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.krazati"
    ],
    "proposition_id": 19,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.krazati:0"
  },
  {
    "id": 20,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ado-trastuzumab emtansine",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kadcyla"
    ],
    "proposition_id": 20,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kadcyla:0"
  },
  {
    "id": 21,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ado-trastuzumab emtansine",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kadcyla"
    ],
    "proposition_id": 20,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kadcyla:1"
  },
  {
    "id": 22,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to afatinib for the first-line treatment of patients with metastatic non-small lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.gilotrif"
    ],
    "proposition_id": 21,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gilotrif:0"
  },
  {
    "id": 23,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to alectinib for the adjuvant treatment of adult patients, following tumor resection, with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive), as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.alecensa"
    ],
    "proposition_id": 22,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.alecensa:0"
  },
  {
    "id": 24,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to alectinib for the adjuvant treatment of adult patients, following tumor resection, with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive), as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.alecensa"
    ],
    "proposition_id": 22,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.alecensa:1"
  },
  {
    "id": 25,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.piqray"
    ],
    "proposition_id": 23,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.piqray:0"
  },
  {
    "id": 26,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.piqray"
    ],
    "proposition_id": 24,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.piqray:0"
  },
  {
    "id": 27,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.piqray"
    ],
    "proposition_id": 25,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.piqray:0"
  },
  {
    "id": 28,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rybrevant"
    ],
    "proposition_id": 26,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rybrevant:0"
  },
  {
    "id": 29,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to amivantamab-vmjw for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rybrevant"
    ],
    "proposition_id": 27,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rybrevant:1"
  },
  {
    "id": 30,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.trisenox"
    ],
    "proposition_id": 28,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.trisenox:0"
  },
  {
    "id": 31,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.trisenox"
    ],
    "proposition_id": 28,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.trisenox:1"
  },
  {
    "id": 32,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.scemblix"
    ],
    "proposition_id": 29,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.scemblix:0"
  },
  {
    "id": 33,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.scemblix"
    ],
    "proposition_id": 30,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.scemblix:1"
  },
  {
    "id": 34,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab for the adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tecentriq"
    ],
    "proposition_id": 31,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tecentriq:0"
  },
  {
    "id": 35,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tecentriq"
    ],
    "proposition_id": 32,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tecentriq:1"
  },
  {
    "id": 36,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tecentriq"
    ],
    "proposition_id": 33,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tecentriq:1"
  },
  {
    "id": 37,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tecentriq"
    ],
    "proposition_id": 34,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tecentriq:2"
  },
  {
    "id": 38,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tecentriq"
    ],
    "proposition_id": 35,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tecentriq:3"
  },
  {
    "id": 39,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tecentriq"
    ],
    "proposition_id": 36,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tecentriq:4"
  },
  {
    "id": 40,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tecentriq"
    ],
    "proposition_id": 37,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tecentriq:4"
  },
  {
    "id": 41,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tecentriq"
    ],
    "proposition_id": 38,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tecentriq:5"
  },
  {
    "id": 42,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tecentriq"
    ],
    "proposition_id": 39,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tecentriq:5"
  },
  {
    "id": 43,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.ayvakit"
    ],
    "proposition_id": 40,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ayvakit:0"
  },
  {
    "id": 44,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mektovi"
    ],
    "proposition_id": 41,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mektovi:0"
  },
  {
    "id": 45,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mektovi"
    ],
    "proposition_id": 42,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mektovi:0"
  },
  {
    "id": 46,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mektovi"
    ],
    "proposition_id": 43,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mektovi:1"
  },
  {
    "id": 47,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "contributions": [
      0,
      3
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 8,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:0"
  },
  {
    "id": 48,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.blincyto"
    ],
    "proposition_id": 45,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.blincyto:0"
  },
  {
    "id": 49,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.blincyto"
    ],
    "proposition_id": 45,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.blincyto:1"
  },
  {
    "id": 50,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.blincyto"
    ],
    "proposition_id": 46,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.blincyto:2"
  },
  {
    "id": 51,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.bosulif"
    ],
    "proposition_id": 47,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.bosulif:0"
  },
  {
    "id": 52,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.bosulif"
    ],
    "proposition_id": 47,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.bosulif:1"
  },
  {
    "id": 54,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.adcetris"
    ],
    "proposition_id": 48,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.adcetris:0"
  },
  {
    "id": 55,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.adcetris"
    ],
    "proposition_id": 49,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.adcetris:1"
  },
  {
    "id": 56,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to brigatinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.alunbrig"
    ],
    "proposition_id": 50,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.alunbrig:0"
  },
  {
    "id": 57,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capecitabine for the treatment of adult patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xeloda"
    ],
    "proposition_id": 51,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xeloda:0"
  },
  {
    "id": 58,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 52,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 59,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 53,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 60,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 54,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 61,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 55,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 62,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 56,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 63,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 57,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 64,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 58,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 65,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 59,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 66,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 60,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 67,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 61,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 68,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 62,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 69,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 63,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 70,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 64,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 71,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 65,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 72,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 66,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 73,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 67,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 74,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 68,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 75,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 69,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 76,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 70,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 77,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 71,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 78,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truqap"
    ],
    "proposition_id": 72,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truqap:0"
  },
  {
    "id": 79,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tabrecta"
    ],
    "proposition_id": 73,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tabrecta:0"
  },
  {
    "id": 80,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tabrecta"
    ],
    "proposition_id": 74,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tabrecta:0"
  },
  {
    "id": 81,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.libtayo"
    ],
    "proposition_id": 75,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.libtayo:0"
  },
  {
    "id": 82,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to cemiplimab for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.libtayo"
    ],
    "proposition_id": 76,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.libtayo:1"
  },
  {
    "id": 83,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ceritinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.zykadia"
    ],
    "proposition_id": 77,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.zykadia:0"
  },
  {
    "id": 84,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to cetuximab in combination with FOLFIRI for the first-line treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer as determined by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.erbitux"
    ],
    "proposition_id": 78,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.erbitux:0"
  },
  {
    "id": 85,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to cetuximab in combination with irinotecan for the treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.erbitux"
    ],
    "proposition_id": 79,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.erbitux:1"
  },
  {
    "id": 86,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to cetuximab for the treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer, as determined by an FDA-approved test, who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.erbitux"
    ],
    "proposition_id": 80,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.erbitux:2"
  },
  {
    "id": 87,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to cetuximab in combination with encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.erbitux"
    ],
    "proposition_id": 81,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.erbitux:3"
  },
  {
    "id": 88,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.cotellic"
    ],
    "proposition_id": 82,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.cotellic:0"
  },
  {
    "id": 89,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.cotellic"
    ],
    "proposition_id": 83,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.cotellic:0"
  },
  {
    "id": 90,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xalkori"
    ],
    "proposition_id": 84,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xalkori:0"
  },
  {
    "id": 91,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xalkori"
    ],
    "proposition_id": 85,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xalkori:0"
  },
  {
    "id": 92,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xalkori"
    ],
    "proposition_id": 86,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xalkori:1"
  },
  {
    "id": 93,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xalkori"
    ],
    "proposition_id": 87,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xalkori:2"
  },
  {
    "id": 94,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tafinlar"
    ],
    "proposition_id": 88,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tafinlar:0"
  },
  {
    "id": 95,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tafinlar"
    ],
    "proposition_id": 89,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tafinlar:1"
  },
  {
    "id": 96,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tafinlar"
    ],
    "proposition_id": 90,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tafinlar:1"
  },
  {
    "id": 97,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tafinlar"
    ],
    "proposition_id": 89,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tafinlar:2"
  },
  {
    "id": 98,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tafinlar"
    ],
    "proposition_id": 90,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tafinlar:2"
  },
  {
    "id": 99,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "contributions": [
      0,
      3
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 6,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:0"
  },
  {
    "id": 100,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tafinlar"
    ],
    "proposition_id": 91,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tafinlar:3"
  },
  {
    "id": 101,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tafinlar"
    ],
    "proposition_id": 92,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tafinlar:4"
  },
  {
    "id": 102,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tafinlar"
    ],
    "proposition_id": 93,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tafinlar:5"
  },
  {
    "id": 103,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tafinlar"
    ],
    "proposition_id": 94,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tafinlar:6"
  },
  {
    "id": 104,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.vizimpro"
    ],
    "proposition_id": 95,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.vizimpro:0"
  },
  {
    "id": 105,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.vizimpro"
    ],
    "proposition_id": 96,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.vizimpro:0"
  },
  {
    "id": 106,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.sprycel"
    ],
    "proposition_id": 97,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.sprycel:0"
  },
  {
    "id": 107,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.sprycel"
    ],
    "proposition_id": 98,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.sprycel:0"
  },
  {
    "id": 108,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.sprycel"
    ],
    "proposition_id": 97,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.sprycel:1"
  },
  {
    "id": 109,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.sprycel"
    ],
    "proposition_id": 98,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.sprycel:1"
  },
  {
    "id": 110,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.sprycel"
    ],
    "proposition_id": 99,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.sprycel:2"
  },
  {
    "id": 111,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.sprycel"
    ],
    "proposition_id": 97,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.sprycel:3"
  },
  {
    "id": 112,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.sprycel"
    ],
    "proposition_id": 98,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.sprycel:3"
  },
  {
    "id": 113,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.sprycel"
    ],
    "proposition_id": 99,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.sprycel:4"
  },
  {
    "id": 114,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dostarlimab in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.jemperli"
    ],
    "proposition_id": 100,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.jemperli:0"
  },
  {
    "id": 115,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dostarlimab in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.jemperli"
    ],
    "proposition_id": 101,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.jemperli:0"
  },
  {
    "id": 116,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.jemperli"
    ],
    "proposition_id": 102,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.jemperli:1"
  },
  {
    "id": 117,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-Approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.jemperli"
    ],
    "proposition_id": 103,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.jemperli:2"
  },
  {
    "id": 118,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imfinzi"
    ],
    "proposition_id": 104,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imfinzi:0"
  },
  {
    "id": 119,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imfinzi"
    ],
    "proposition_id": 105,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imfinzi:0"
  },
  {
    "id": 120,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imfinzi"
    ],
    "proposition_id": 106,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imfinzi:0"
  },
  {
    "id": 121,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imfinzi"
    ],
    "proposition_id": 107,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imfinzi:0"
  },
  {
    "id": 122,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imfinzi"
    ],
    "proposition_id": 108,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imfinzi:0"
  },
  {
    "id": 123,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to durvalumab in combination with carboplatin and paclitaxel, followed by durvalumab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imfinzi"
    ],
    "proposition_id": 109,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imfinzi:1"
  },
  {
    "id": 124,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to elacestrant for the treatment of patients who are postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.orserdu"
    ],
    "proposition_id": 110,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.orserdu:0"
  },
  {
    "id": 125,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.idhifa"
    ],
    "proposition_id": 111,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.idhifa:0"
  },
  {
    "id": 126,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.idhifa"
    ],
    "proposition_id": 112,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.idhifa:0"
  },
  {
    "id": 127,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.idhifa"
    ],
    "proposition_id": 113,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.idhifa:0"
  },
  {
    "id": 128,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.idhifa"
    ],
    "proposition_id": 114,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.idhifa:0"
  },
  {
    "id": 129,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.idhifa"
    ],
    "proposition_id": 115,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.idhifa:0"
  },
  {
    "id": 130,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.idhifa"
    ],
    "proposition_id": 116,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.idhifa:0"
  },
  {
    "id": 131,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.idhifa"
    ],
    "proposition_id": 117,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.idhifa:0"
  },
  {
    "id": 132,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.idhifa"
    ],
    "proposition_id": 118,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.idhifa:0"
  },
  {
    "id": 133,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.idhifa"
    ],
    "proposition_id": 119,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.idhifa:0"
  },
  {
    "id": 134,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.braftovi"
    ],
    "proposition_id": 41,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.braftovi:0"
  },
  {
    "id": 135,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.braftovi"
    ],
    "proposition_id": 42,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.braftovi:0"
  },
  {
    "id": 136,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to cetuximab in combination with encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.braftovi"
    ],
    "proposition_id": 81,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.braftovi:1"
  },
  {
    "id": 137,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.braftovi"
    ],
    "proposition_id": 43,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.braftovi:2"
  },
  {
    "id": 138,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to entrectinib for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rozlytrek"
    ],
    "proposition_id": 120,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rozlytrek:0"
  },
  {
    "id": 139,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rozlytrek"
    ],
    "proposition_id": 121,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rozlytrek:1"
  },
  {
    "id": 140,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rozlytrek"
    ],
    "proposition_id": 122,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rozlytrek:1"
  },
  {
    "id": 141,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rozlytrek"
    ],
    "proposition_id": 123,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rozlytrek:1"
  },
  {
    "id": 142,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.balversa"
    ],
    "proposition_id": 124,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.balversa:0"
  },
  {
    "id": 143,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.balversa"
    ],
    "proposition_id": 125,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.balversa:0"
  },
  {
    "id": 144,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.balversa"
    ],
    "proposition_id": 126,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.balversa:0"
  },
  {
    "id": 145,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.balversa"
    ],
    "proposition_id": 127,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.balversa:0"
  },
  {
    "id": 146,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.balversa"
    ],
    "proposition_id": 128,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.balversa:0"
  },
  {
    "id": 147,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to erlotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test, receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Erlotnib's product label further states that safety and efficacy of erlotnib have not been established in patients with NSCLC whose tumors have other EGFR mutations. Furthermore, the product label states that it is not recommended for use in combination with platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tarceva"
    ],
    "proposition_id": 129,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tarceva:0"
  },
  {
    "id": 148,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to erlotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test, receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Erlotnib's product label further states that safety and efficacy of erlotnib have not been established in patients with NSCLC whose tumors have other EGFR mutations. Furthermore, the product label states that it is not recommended for use in combination with platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tarceva"
    ],
    "proposition_id": 130,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tarceva:0"
  },
  {
    "id": 149,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.afinitor"
    ],
    "proposition_id": 131,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.afinitor:0"
  },
  {
    "id": 150,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.afinitor"
    ],
    "proposition_id": 132,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.afinitor:0"
  },
  {
    "id": 151,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.afinitor"
    ],
    "proposition_id": 133,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.afinitor:0"
  },
  {
    "id": 152,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 134,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:0"
  },
  {
    "id": 153,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 135,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:0"
  },
  {
    "id": 154,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 136,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:0"
  },
  {
    "id": 155,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 137,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:1"
  },
  {
    "id": 156,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 138,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:1"
  },
  {
    "id": 157,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 139,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:1"
  },
  {
    "id": 158,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 140,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:2"
  },
  {
    "id": 159,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 141,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:2"
  },
  {
    "id": 160,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 142,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:2"
  },
  {
    "id": 161,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 143,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:3"
  },
  {
    "id": 162,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 144,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:3"
  },
  {
    "id": 163,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 145,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:3"
  },
  {
    "id": 164,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 9,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:3"
  },
  {
    "id": 165,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 10,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:3"
  },
  {
    "id": 166,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.faslodex"
    ],
    "proposition_id": 11,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.faslodex:3"
  },
  {
    "id": 167,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to futibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. Futibatinib's package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lytgobi"
    ],
    "proposition_id": 146,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lytgobi:0"
  },
  {
    "id": 168,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to gefitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. Gefitinib's package insert includes the following limitation of use: safety and efficacy of gefitinib have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.iressa"
    ],
    "proposition_id": 147,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.iressa:0"
  },
  {
    "id": 169,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to gefitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. Gefitinib's package insert includes the following limitation of use: safety and efficacy of gefitinib have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.iressa"
    ],
    "proposition_id": 148,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.iressa:0"
  },
  {
    "id": 170,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to gemtuzumab ozogamicin for the treatment of adult and pediatric patients aged 1 month or older with newly-diagnosed CD33-positive acute myeloid leukemia (AML).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mylotarg"
    ],
    "proposition_id": 149,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mylotarg:0"
  },
  {
    "id": 171,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to gemtuzumab ozogamicin for the treatment of adult and pediatric patients aged 1 month or older with newly-diagnosed CD33-positive acute myeloid leukemia (AML).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mylotarg"
    ],
    "proposition_id": 149,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mylotarg:1"
  },
  {
    "id": 172,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xospata"
    ],
    "proposition_id": 150,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xospata:0"
  },
  {
    "id": 173,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xospata"
    ],
    "proposition_id": 151,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xospata:0"
  },
  {
    "id": 174,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xospata"
    ],
    "proposition_id": 152,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xospata:0"
  },
  {
    "id": 175,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xospata"
    ],
    "proposition_id": 153,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xospata:0"
  },
  {
    "id": 176,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xospata"
    ],
    "proposition_id": 154,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xospata:0"
  },
  {
    "id": 177,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xospata"
    ],
    "proposition_id": 155,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xospata:0"
  },
  {
    "id": 178,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xospata"
    ],
    "proposition_id": 156,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xospata:0"
  },
  {
    "id": 179,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.xospata"
    ],
    "proposition_id": 157,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.xospata:0"
  },
  {
    "id": 180,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.gleevec"
    ],
    "proposition_id": 158,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gleevec:0"
  },
  {
    "id": 181,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.gleevec"
    ],
    "proposition_id": 159,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gleevec:0"
  },
  {
    "id": 182,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.gleevec"
    ],
    "proposition_id": 158,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gleevec:1"
  },
  {
    "id": 183,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.gleevec"
    ],
    "proposition_id": 159,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gleevec:1"
  },
  {
    "id": 184,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.gleevec"
    ],
    "proposition_id": 160,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gleevec:2"
  },
  {
    "id": 185,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.gleevec"
    ],
    "proposition_id": 160,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gleevec:3"
  },
  {
    "id": 186,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.gleevec"
    ],
    "proposition_id": 161,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gleevec:4"
  },
  {
    "id": 187,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.gleevec"
    ],
    "proposition_id": 162,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gleevec:4"
  },
  {
    "id": 188,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.gleevec"
    ],
    "proposition_id": 163,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gleevec:5"
  },
  {
    "id": 189,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.gleevec"
    ],
    "proposition_id": 164,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gleevec:6"
  },
  {
    "id": 190,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.gleevec"
    ],
    "proposition_id": 165,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gleevec:7"
  },
  {
    "id": 191,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the adjuvant treatment of adult patients following resection of Kit (CD117) positive gastrointestinal stromal tumors (GIST).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.gleevec"
    ],
    "proposition_id": 166,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gleevec:8"
  },
  {
    "id": 192,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to infigratinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.truseltiq"
    ],
    "proposition_id": 167,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.truseltiq:0"
  },
  {
    "id": 193,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to inotuzumab ozogamicin for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.besponsa"
    ],
    "proposition_id": 168,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.besponsa:0"
  },
  {
    "id": 194,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.",
    "contributions": [
      0,
      4
    ],
    "reportedIn": [
      "doc:fda.yervoy"
    ],
    "proposition_id": 169,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.yervoy:0"
  },
  {
    "id": 195,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.",
    "contributions": [
      0,
      4
    ],
    "reportedIn": [
      "doc:fda.yervoy"
    ],
    "proposition_id": 507,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.yervoy:0"
  },
  {
    "id": 196,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>=1%), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.yervoy"
    ],
    "proposition_id": 171,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.yervoy:1"
  },
  {
    "id": 197,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.yervoy"
    ],
    "proposition_id": 172,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.yervoy:2"
  },
  {
    "id": 198,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.yervoy"
    ],
    "proposition_id": 173,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.yervoy:2"
  },
  {
    "id": 199,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.yervoy"
    ],
    "proposition_id": 174,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.yervoy:2"
  },
  {
    "id": 200,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 175,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:0"
  },
  {
    "id": 201,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 176,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:0"
  },
  {
    "id": 202,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 177,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:0"
  },
  {
    "id": 203,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 178,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:0"
  },
  {
    "id": 204,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 179,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:0"
  },
  {
    "id": 205,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 180,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:0"
  },
  {
    "id": 206,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 181,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:0"
  },
  {
    "id": 207,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 182,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:0"
  },
  {
    "id": 208,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 183,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:0"
  },
  {
    "id": 209,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 184,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:0"
  },
  {
    "id": 210,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 175,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:1"
  },
  {
    "id": 211,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 176,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:1"
  },
  {
    "id": 212,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 177,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:1"
  },
  {
    "id": 213,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 178,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:1"
  },
  {
    "id": 214,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 179,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:1"
  },
  {
    "id": 215,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 185,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:2"
  },
  {
    "id": 216,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 186,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:2"
  },
  {
    "id": 217,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 187,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:2"
  },
  {
    "id": 218,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 188,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:2"
  },
  {
    "id": 219,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 189,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:2"
  },
  {
    "id": 220,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 190,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:3"
  },
  {
    "id": 221,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 191,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:3"
  },
  {
    "id": 222,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 192,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:3"
  },
  {
    "id": 223,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 193,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:3"
  },
  {
    "id": 224,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tibsovo"
    ],
    "proposition_id": 194,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tibsovo:3"
  },
  {
    "id": 225,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to lapatinib in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, a trastuzumab.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tykerb"
    ],
    "proposition_id": 195,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tykerb:0"
  },
  {
    "id": 226,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tykerb"
    ],
    "proposition_id": 196,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tykerb:1"
  },
  {
    "id": 227,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tykerb"
    ],
    "proposition_id": 197,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tykerb:1"
  },
  {
    "id": 228,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tykerb"
    ],
    "proposition_id": 198,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tykerb:1"
  },
  {
    "id": 229,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.",
    "contributions": [
      0,
      5
    ],
    "reportedIn": [
      "doc:fda.vitrakvi"
    ],
    "proposition_id": 199,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.vitrakvi:0"
  },
  {
    "id": 230,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.",
    "contributions": [
      0,
      5
    ],
    "reportedIn": [
      "doc:fda.vitrakvi"
    ],
    "proposition_id": 200,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.vitrakvi:0"
  },
  {
    "id": 231,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.",
    "contributions": [
      0,
      5
    ],
    "reportedIn": [
      "doc:fda.vitrakvi"
    ],
    "proposition_id": 201,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.vitrakvi:0"
  },
  {
    "id": 232,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to lenalidomide for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.revlimid"
    ],
    "proposition_id": 202,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.revlimid:0"
  },
  {
    "id": 233,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to lorlatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lorbrena"
    ],
    "proposition_id": 203,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lorbrena:0"
  },
  {
    "id": 234,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.margenza"
    ],
    "proposition_id": 204,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.margenza:0"
  },
  {
    "id": 235,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.margenza"
    ],
    "proposition_id": 205,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.margenza:0"
  },
  {
    "id": 236,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.margenza"
    ],
    "proposition_id": 206,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.margenza:0"
  },
  {
    "id": 237,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.margenza"
    ],
    "proposition_id": 207,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.margenza:0"
  },
  {
    "id": 238,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rydapt"
    ],
    "proposition_id": 208,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rydapt:0"
  },
  {
    "id": 239,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rydapt"
    ],
    "proposition_id": 209,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rydapt:0"
  },
  {
    "id": 240,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rydapt"
    ],
    "proposition_id": 210,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rydapt:0"
  },
  {
    "id": 241,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rydapt"
    ],
    "proposition_id": 211,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rydapt:0"
  },
  {
    "id": 242,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rydapt"
    ],
    "proposition_id": 212,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rydapt:0"
  },
  {
    "id": 243,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rydapt"
    ],
    "proposition_id": 213,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rydapt:0"
  },
  {
    "id": 244,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rydapt"
    ],
    "proposition_id": 214,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rydapt:0"
  },
  {
    "id": 245,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rydapt"
    ],
    "proposition_id": 215,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rydapt:0"
  },
  {
    "id": 246,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rydapt"
    ],
    "proposition_id": 216,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rydapt:0"
  },
  {
    "id": 247,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rydapt"
    ],
    "proposition_id": 217,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rydapt:0"
  },
  {
    "id": 248,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.exkivity"
    ],
    "proposition_id": 218,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.exkivity:0"
  },
  {
    "id": 249,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to neratinib for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab based therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.nerlynx"
    ],
    "proposition_id": 219,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.nerlynx:0"
  },
  {
    "id": 250,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.nerlynx"
    ],
    "proposition_id": 220,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.nerlynx:1"
  },
  {
    "id": 251,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tasigna"
    ],
    "proposition_id": 221,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tasigna:0"
  },
  {
    "id": 252,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tasigna"
    ],
    "proposition_id": 222,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tasigna:0"
  },
  {
    "id": 253,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.tasigna"
    ],
    "proposition_id": 221,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tasigna:1"
  },
  {
    "id": 254,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.tasigna"
    ],
    "proposition_id": 222,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tasigna:1"
  },
  {
    "id": 255,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.zejula"
    ],
    "proposition_id": 223,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.zejula:0"
  },
  {
    "id": 256,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.zejula"
    ],
    "proposition_id": 224,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.zejula:0"
  },
  {
    "id": 257,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.zejula"
    ],
    "proposition_id": 225,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.zejula:0"
  },
  {
    "id": 258,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.zejula"
    ],
    "proposition_id": 226,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.zejula:0"
  },
  {
    "id": 259,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.zejula"
    ],
    "proposition_id": 227,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.zejula:0"
  },
  {
    "id": 260,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.zejula"
    ],
    "proposition_id": 228,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.zejula:0"
  },
  {
    "id": 261,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.opdivo"
    ],
    "proposition_id": 229,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.opdivo:0"
  },
  {
    "id": 262,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>= 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.opdivo"
    ],
    "proposition_id": 230,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.opdivo:1"
  },
  {
    "id": 263,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 231,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:0"
  },
  {
    "id": 264,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 232,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:0"
  },
  {
    "id": 265,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 233,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:0"
  },
  {
    "id": 266,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 234,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:0"
  },
  {
    "id": 267,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 235,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:0"
  },
  {
    "id": 268,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 236,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:0"
  },
  {
    "id": 269,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 237,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:0"
  },
  {
    "id": 270,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 238,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:0"
  },
  {
    "id": 271,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 239,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:0"
  },
  {
    "id": 272,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 240,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:0"
  },
  {
    "id": 273,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 241,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:0"
  },
  {
    "id": 274,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 242,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:0"
  },
  {
    "id": 275,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 243,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 276,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 244,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 277,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 245,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 278,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 246,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 279,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 247,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 280,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 248,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 281,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 249,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 282,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 250,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 283,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 251,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 284,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 252,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 285,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 253,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 286,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 254,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 287,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 255,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 288,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 256,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 289,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 257,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:1"
  },
  {
    "id": 290,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 231,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:2"
  },
  {
    "id": 291,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 232,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:2"
  },
  {
    "id": 292,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 233,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:2"
  },
  {
    "id": 293,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 234,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:2"
  },
  {
    "id": 294,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 235,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:2"
  },
  {
    "id": 295,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 236,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:2"
  },
  {
    "id": 296,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 237,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:2"
  },
  {
    "id": 297,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 238,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:2"
  },
  {
    "id": 298,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 239,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:2"
  },
  {
    "id": 299,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 240,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:2"
  },
  {
    "id": 300,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 241,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:2"
  },
  {
    "id": 301,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 242,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:2"
  },
  {
    "id": 302,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 258,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:3"
  },
  {
    "id": 303,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 259,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:3"
  },
  {
    "id": 304,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 258,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:4"
  },
  {
    "id": 305,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 259,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:4"
  },
  {
    "id": 306,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 260,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:5"
  },
  {
    "id": 307,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 261,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:5"
  },
  {
    "id": 308,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 262,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 309,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 263,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 310,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 264,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 311,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 265,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 312,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 266,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 313,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 267,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 314,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 268,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 315,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 269,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 316,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 270,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 317,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 271,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 318,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 272,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 319,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 273,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 320,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 274,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 321,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 275,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 322,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 276,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 323,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 277,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 324,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 278,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 325,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 279,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 326,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 280,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 327,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 281,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 328,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 282,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 329,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 283,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 330,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 284,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 331,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 285,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 332,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 286,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 333,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 287,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 334,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 288,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 335,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 289,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 336,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 290,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:6"
  },
  {
    "id": 337,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 291,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:7"
  },
  {
    "id": 338,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 292,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:7"
  },
  {
    "id": 339,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 293,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:7"
  },
  {
    "id": 340,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 294,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:7"
  },
  {
    "id": 341,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 295,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:7"
  },
  {
    "id": 342,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 296,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:7"
  },
  {
    "id": 343,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 297,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:7"
  },
  {
    "id": 344,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lynparza"
    ],
    "proposition_id": 298,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lynparza:7"
  },
  {
    "id": 345,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rezlidhia"
    ],
    "proposition_id": 299,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rezlidhia:0"
  },
  {
    "id": 346,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rezlidhia"
    ],
    "proposition_id": 300,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rezlidhia:0"
  },
  {
    "id": 347,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rezlidhia"
    ],
    "proposition_id": 301,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rezlidhia:0"
  },
  {
    "id": 348,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rezlidhia"
    ],
    "proposition_id": 302,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rezlidhia:0"
  },
  {
    "id": 349,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rezlidhia"
    ],
    "proposition_id": 303,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rezlidhia:0"
  },
  {
    "id": 350,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tagrisso"
    ],
    "proposition_id": 304,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tagrisso:0"
  },
  {
    "id": 351,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tagrisso"
    ],
    "proposition_id": 305,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tagrisso:0"
  },
  {
    "id": 352,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tagrisso"
    ],
    "proposition_id": 305,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tagrisso:1"
  },
  {
    "id": 353,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tagrisso"
    ],
    "proposition_id": 304,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tagrisso:1"
  },
  {
    "id": 354,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tagrisso"
    ],
    "proposition_id": 306,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tagrisso:2"
  },
  {
    "id": 355,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tagrisso"
    ],
    "proposition_id": 307,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tagrisso:2"
  },
  {
    "id": 356,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tagrisso"
    ],
    "proposition_id": 308,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tagrisso:2"
  },
  {
    "id": 357,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tagrisso"
    ],
    "proposition_id": 309,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tagrisso:2"
  },
  {
    "id": 358,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tagrisso"
    ],
    "proposition_id": 310,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tagrisso:3"
  },
  {
    "id": 359,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.ibrance"
    ],
    "proposition_id": 311,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ibrance:0"
  },
  {
    "id": 360,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.ibrance"
    ],
    "proposition_id": 312,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ibrance:0"
  },
  {
    "id": 361,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.ibrance"
    ],
    "proposition_id": 313,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ibrance:0"
  },
  {
    "id": 362,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.ibrance"
    ],
    "proposition_id": 143,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ibrance:1"
  },
  {
    "id": 363,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.ibrance"
    ],
    "proposition_id": 144,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ibrance:1"
  },
  {
    "id": 364,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.ibrance"
    ],
    "proposition_id": 145,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ibrance:1"
  },
  {
    "id": 365,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to panitumumab in combination with FOLFOX for the first-line treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS, as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC). The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.vectibix"
    ],
    "proposition_id": 314,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.vectibix:0"
  },
  {
    "id": 366,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to panitumumab for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC)following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.vectibix"
    ],
    "proposition_id": 315,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.vectibix:1"
  },
  {
    "id": 367,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is based on KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in 616 patients where the choice of platinum-containing chemotherapy was either carboplatin or cisplatin.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 316,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:0"
  },
  {
    "id": 368,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is based on KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in 616 patients where the choice of platinum-containing chemotherapy was either carboplatin or cisplatin.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 317,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:0"
  },
  {
    "id": 369,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the first-line treatment of patients with non-small cell lung cancer expressing PD-L1 [Tumor Proportion Score (TPS) >=1%], as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 318,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:1"
  },
  {
    "id": 370,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 [Tumor Proportion Score (TPS) >=1%], as determined by an FDA-approved test, with disease progression on or after platinum containing chemotherapy. The product label further states that patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 319,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:2"
  },
  {
    "id": 371,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) >=1] as determined by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 320,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:3"
  },
  {
    "id": 372,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 321,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:4"
  },
  {
    "id": 373,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 322,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:4"
  },
  {
    "id": 374,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), as determined by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 323,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:5"
  },
  {
    "id": 375,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), as determined by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 324,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:5"
  },
  {
    "id": 376,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. The product label notes that this indication is approved under accelerated approval based on tumor response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. This indication is based on KEYNOTE-811 (NCT03615326), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of chemotherapy between either cisplatin and 5-fu, or oxaliplatin and capecitabine.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 325,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:6"
  },
  {
    "id": 377,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. The product label notes that this indication is approved under accelerated approval based on tumor response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. This indication is based on KEYNOTE-811 (NCT03615326), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of chemotherapy between either cisplatin and 5-fu, or oxaliplatin and capecitabine.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 326,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:6"
  },
  {
    "id": 378,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This indication is based on KEYNOTE-859 (NCT03675737), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of combination chemotherapy of either cisplatin and 5-fu or oxaliplatin and capecitabine.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 327,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:7"
  },
  {
    "id": 379,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This indication is based on KEYNOTE-859 (NCT03675737), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of combination chemotherapy of either cisplatin and 5-fu or oxaliplatin and capecitabine.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 328,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:7"
  },
  {
    "id": 380,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10), as determined by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 329,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:8"
  },
  {
    "id": 381,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10), as determined by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 330,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:8"
  },
  {
    "id": 382,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 331,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:9"
  },
  {
    "id": 383,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 332,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:9"
  },
  {
    "id": 384,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 333,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:9"
  },
  {
    "id": 385,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 334,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:9"
  },
  {
    "id": 386,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 335,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:9"
  },
  {
    "id": 387,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 336,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:9"
  },
  {
    "id": 388,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 337,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:9"
  },
  {
    "id": 389,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 338,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:9"
  },
  {
    "id": 390,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 339,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:10"
  },
  {
    "id": 391,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 340,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:10"
  },
  {
    "id": 392,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with lenvatinib for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 341,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:11"
  },
  {
    "id": 393,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is mismatch repair deficient (MMRd) or microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 342,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:12"
  },
  {
    "id": 394,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is mismatch repair deficient (MMRd) or microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 343,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:12"
  },
  {
    "id": 395,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. The product label states that the safety and effectiveness of pembrolizumab in pediatric patients with TMB-H central nervous system cancers have not been established and that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, it states that continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 344,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:13"
  },
  {
    "id": 396,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then pembrolizumab continued as a single agent as adjuvant treatment after surgery, of patients with high-risk early-stage triple negative breast cancer (TNBC). This indication is based on KEYNOTE-522 (NCT03036488), a randomized (2:1), multicenter, double-blind, placebo-controlled trial where the chemotherapy regimen consisted of carboplatin, paclitaxel, doxorubicin, and cyclophosphamide.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 345,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:14"
  },
  {
    "id": 397,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (CPS >= 10), as determined by an FDA approved test. This indication is based on KEYNOTE-355 (NCT02819518), a multicenter, double-blind, randomized, placebo-controlled trial where patients received either paclitaxel and paclitaxel protein-bound, or gemcitabine and carboplatin.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 346,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:15"
  },
  {
    "id": 398,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (CPS >= 10), as determined by an FDA approved test. This indication is based on KEYNOTE-355 (NCT02819518), a multicenter, double-blind, randomized, placebo-controlled trial where patients received either paclitaxel and paclitaxel protein-bound, or gemcitabine and carboplatin.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 347,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:15"
  },
  {
    "id": 399,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to pemigatinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.pemazyre"
    ],
    "proposition_id": 348,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.pemazyre:0"
  },
  {
    "id": 400,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to pemigatinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.pemazyre"
    ],
    "proposition_id": 349,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.pemazyre:0"
  },
  {
    "id": 401,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pemigatinib for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.pemazyre"
    ],
    "proposition_id": 350,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.pemazyre:1"
  },
  {
    "id": 402,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.perjeta"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.perjeta:0"
  },
  {
    "id": 403,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.perjeta"
    ],
    "proposition_id": 352,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.perjeta:1"
  },
  {
    "id": 404,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.perjeta"
    ],
    "proposition_id": 353,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.perjeta:1"
  },
  {
    "id": 405,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.phesgo"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.phesgo:2"
  },
  {
    "id": 406,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.perjeta"
    ],
    "proposition_id": 354,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.perjeta:2"
  },
  {
    "id": 407,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.perjeta"
    ],
    "proposition_id": 355,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.perjeta:2"
  },
  {
    "id": 408,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.perjeta"
    ],
    "proposition_id": 356,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.perjeta:2"
  },
  {
    "id": 409,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.perjeta"
    ],
    "proposition_id": 357,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.perjeta:2"
  },
  {
    "id": 410,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.perjeta"
    ],
    "proposition_id": 358,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.perjeta:2"
  },
  {
    "id": 411,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.perjeta"
    ],
    "proposition_id": 359,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.perjeta:2"
  },
  {
    "id": 412,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.phesgo"
    ],
    "proposition_id": 353,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.phesgo:1"
  },
  {
    "id": 413,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.perjeta"
    ],
    "proposition_id": 360,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.perjeta:2"
  },
  {
    "id": 414,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.phesgo"
    ],
    "proposition_id": 352,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.phesgo:0"
  },
  {
    "id": 415,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.phesgo"
    ],
    "proposition_id": 353,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.phesgo:0"
  },
  {
    "id": 416,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.phesgo"
    ],
    "proposition_id": 360,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.phesgo:1"
  },
  {
    "id": 417,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.phesgo"
    ],
    "proposition_id": 354,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.phesgo:1"
  },
  {
    "id": 418,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.phesgo"
    ],
    "proposition_id": 355,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.phesgo:1"
  },
  {
    "id": 419,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.phesgo"
    ],
    "proposition_id": 356,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.phesgo:1"
  },
  {
    "id": 420,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.phesgo"
    ],
    "proposition_id": 357,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.phesgo:1"
  },
  {
    "id": 421,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.phesgo"
    ],
    "proposition_id": 358,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.phesgo:1"
  },
  {
    "id": 422,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.phesgo"
    ],
    "proposition_id": 359,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.phesgo:1"
  },
  {
    "id": 423,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.phesgo"
    ],
    "proposition_id": 352,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.phesgo:1"
  },
  {
    "id": 424,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.perjeta"
    ],
    "proposition_id": 352,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.perjeta:2"
  },
  {
    "id": 425,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.perjeta"
    ],
    "proposition_id": 353,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.perjeta:2"
  },
  {
    "id": 426,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The product label notes that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). This indication is based on PhALLCON (NCT03589326), a randomized, active-controlled, multicenter, open-label trial in which chemotherapy regimens were: vincristine and dexamethasone (induction, cycles 1 to 3); methotrexate and cytarabine (consolidation, cycles 4 to 9, alternating methotrexate and cytarabine); and vincristine and prednisone (maintenance, cycles 10 to 20).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.iclusig"
    ],
    "proposition_id": 361,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.iclusig:0"
  },
  {
    "id": 427,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.iclusig"
    ],
    "proposition_id": 362,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.iclusig:1"
  },
  {
    "id": 428,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or blast phase. The product label states the following limitations of use: ponatinib is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.iclusig"
    ],
    "proposition_id": 363,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.iclusig:2"
  },
  {
    "id": 429,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pralsetinib for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as detected by an FDA approved test (NSCLC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.gavreto"
    ],
    "proposition_id": 364,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gavreto:0"
  },
  {
    "id": 430,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). This indication is based on ARROW (NCT03037385), a multicenter, open-label, multi-cohort clinical trial where all enrolled patients had papillary thyroid cancer.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.gavreto"
    ],
    "proposition_id": 365,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.gavreto:1"
  },
  {
    "id": 431,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.cyramza"
    ],
    "proposition_id": 366,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.cyramza:0"
  },
  {
    "id": 432,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.cyramza"
    ],
    "proposition_id": 367,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.cyramza:0"
  },
  {
    "id": 433,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.augtyro"
    ],
    "proposition_id": 368,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.augtyro:0"
  },
  {
    "id": 434,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.augtyro"
    ],
    "proposition_id": 369,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.augtyro:1"
  },
  {
    "id": 435,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.augtyro"
    ],
    "proposition_id": 370,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.augtyro:1"
  },
  {
    "id": 436,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.augtyro"
    ],
    "proposition_id": 371,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.augtyro:1"
  },
  {
    "id": 437,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 372,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:0"
  },
  {
    "id": 438,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 373,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:0"
  },
  {
    "id": 439,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 374,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:0"
  },
  {
    "id": 440,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 375,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:0"
  },
  {
    "id": 441,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 376,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:0"
  },
  {
    "id": 442,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 377,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:0"
  },
  {
    "id": 443,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 140,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:1"
  },
  {
    "id": 444,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 141,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:1"
  },
  {
    "id": 445,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 142,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:1"
  },
  {
    "id": 446,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B-cell Non-Hodgkin's Lymphoma (NHL).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rituxan"
    ],
    "proposition_id": 378,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rituxan:0"
  },
  {
    "id": 447,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rituxan"
    ],
    "proposition_id": 379,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rituxan:1"
  },
  {
    "id": 448,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rituxan"
    ],
    "proposition_id": 380,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rituxan:1"
  },
  {
    "id": 449,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rituxan"
    ],
    "proposition_id": 381,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rituxan:1"
  },
  {
    "id": 451,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens for the treatment of adult patients with previously untreated diffuse large B-cell, CD20-positive Non-Hodgkin's Lymphoma (NHL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrolled of 1854 patients. The product label did not specify the name of the clinical trial name (Study 9) that administered an anthracycline-containing chemotherapy regimen, or what the specific regimen was.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.rituxan"
    ],
    "proposition_id": 382,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rituxan:2"
  },
  {
    "id": 452,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens for the treatment of adult patients with previously untreated diffuse large B-cell, CD20-positive Non-Hodgkin's Lymphoma (NHL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrolled of 1854 patients. The product label did not specify the name of the clinical trial name (Study 9) that administered an anthracycline-containing chemotherapy regimen, or what the specific regimen was.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rituxan"
    ],
    "proposition_id": 382,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rituxan:3"
  },
  {
    "id": 453,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rituxan"
    ],
    "proposition_id": 383,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rituxan:4"
  },
  {
    "id": 454,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rituxan"
    ],
    "proposition_id": 384,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rituxan:4"
  },
  {
    "id": 455,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rituxan"
    ],
    "proposition_id": 385,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rituxan:4"
  },
  {
    "id": 456,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab in combination with fludarabine and cyclophosphamide for the treatment of previously untreated and previously treated CD20-positive Chronic Lymphocytic Leukemia (CLL).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rituxan"
    ],
    "proposition_id": 386,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rituxan:5"
  },
  {
    "id": 457,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 387,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:0"
  },
  {
    "id": 458,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 388,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:0"
  },
  {
    "id": 459,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 389,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:0"
  },
  {
    "id": 460,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 390,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:0"
  },
  {
    "id": 461,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 391,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:0"
  },
  {
    "id": 462,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 392,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:0"
  },
  {
    "id": 463,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 393,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:0"
  },
  {
    "id": 464,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 394,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:0"
  },
  {
    "id": 465,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 395,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:0"
  },
  {
    "id": 466,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 396,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:0"
  },
  {
    "id": 467,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 397,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:0"
  },
  {
    "id": 468,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 398,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:0"
  },
  {
    "id": 469,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 399,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:1"
  },
  {
    "id": 470,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 400,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:1"
  },
  {
    "id": 471,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 401,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:1"
  },
  {
    "id": 472,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rubraca"
    ],
    "proposition_id": 402,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rubraca:1"
  },
  {
    "id": 473,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.trodelvy"
    ],
    "proposition_id": 403,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.trodelvy:0"
  },
  {
    "id": 474,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.trodelvy"
    ],
    "proposition_id": 404,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.trodelvy:1"
  },
  {
    "id": 475,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.trodelvy"
    ],
    "proposition_id": 405,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.trodelvy:1"
  },
  {
    "id": 476,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.trodelvy"
    ],
    "proposition_id": 406,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.trodelvy:1"
  },
  {
    "id": 477,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.retevmo"
    ],
    "proposition_id": 407,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.retevmo:0"
  },
  {
    "id": 478,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.retevmo"
    ],
    "proposition_id": 408,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.retevmo:1"
  },
  {
    "id": 479,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to selpercatinib for the treatment of treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.retevmo"
    ],
    "proposition_id": 409,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.retevmo:2"
  },
  {
    "id": 480,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.retevmo"
    ],
    "proposition_id": 410,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.retevmo:3"
  },
  {
    "id": 481,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to sotorasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. The product label states that this indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lumakras"
    ],
    "proposition_id": 411,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lumakras:0"
  },
  {
    "id": 482,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for Talazoparib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 412,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:0"
  },
  {
    "id": 483,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for Talazoparib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 413,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:0"
  },
  {
    "id": 484,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tepmetko"
    ],
    "proposition_id": 414,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tepmetko:0"
  },
  {
    "id": 485,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tepmetko"
    ],
    "proposition_id": 415,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tepmetko:0"
  },
  {
    "id": 486,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to trametinib for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mekinist"
    ],
    "proposition_id": 416,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mekinist:0"
  },
  {
    "id": 487,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to trametinib for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.mekinist"
    ],
    "proposition_id": 417,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mekinist:0"
  },
  {
    "id": 488,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mekinist"
    ],
    "proposition_id": 89,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mekinist:1"
  },
  {
    "id": 489,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mekinist"
    ],
    "proposition_id": 90,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mekinist:1"
  },
  {
    "id": 490,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mekinist"
    ],
    "proposition_id": 91,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mekinist:3"
  },
  {
    "id": 491,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mekinist"
    ],
    "proposition_id": 92,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mekinist:4"
  },
  {
    "id": 492,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mekinist"
    ],
    "proposition_id": 93,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mekinist:5"
  },
  {
    "id": 493,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mekinist"
    ],
    "proposition_id": 94,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mekinist:6"
  },
  {
    "id": 494,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to trastuzumab for the treatment of patients with HER2-overexpressing breast cancer. The product label specifies to select  patients for therapy based on an FDA-approved companion diagnostic for herceptin.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.herceptin"
    ],
    "proposition_id": 418,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.herceptin:0"
  },
  {
    "id": 495,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to trastuzumab for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.herceptin"
    ],
    "proposition_id": 419,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.herceptin:1"
  },
  {
    "id": 496,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either (i) in the metastatic setting, or (ii) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.enhertu"
    ],
    "proposition_id": 420,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.enhertu:0"
  },
  {
    "id": 497,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.enhertu"
    ],
    "proposition_id": 421,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.enhertu:1"
  },
  {
    "id": 498,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. The product label states that these indications are approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.enhertu"
    ],
    "proposition_id": 422,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.enhertu:2"
  },
  {
    "id": 499,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.enhertu"
    ],
    "proposition_id": 423,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.enhertu:3"
  },
  {
    "id": 500,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. The product label states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.enhertu"
    ],
    "proposition_id": 424,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.enhertu:4"
  },
  {
    "id": 501,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tukysa"
    ],
    "proposition_id": 425,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tukysa:0"
  },
  {
    "id": 502,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.zelboraf"
    ],
    "proposition_id": 426,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.zelboraf:0"
  },
  {
    "id": 503,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with Erdheim-Chester Disease and a BRAF V600 mutation.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.zelboraf"
    ],
    "proposition_id": 427,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.zelboraf:1"
  },
  {
    "id": 504,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with Erdheim-Chester Disease and a BRAF V600 mutation.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.zelboraf"
    ],
    "proposition_id": 428,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.zelboraf:1"
  },
  {
    "id": 505,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tazverik"
    ],
    "proposition_id": 429,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tazverik:0"
  },
  {
    "id": 506,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tazverik"
    ],
    "proposition_id": 430,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tazverik:0"
  },
  {
    "id": 507,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tazverik"
    ],
    "proposition_id": 431,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tazverik:0"
  },
  {
    "id": 508,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tazverik"
    ],
    "proposition_id": 432,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tazverik:0"
  },
  {
    "id": 509,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tazverik"
    ],
    "proposition_id": 433,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tazverik:0"
  },
  {
    "id": 510,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tazverik"
    ],
    "proposition_id": 434,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tazverik:0"
  },
  {
    "id": 511,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tazverik"
    ],
    "proposition_id": 435,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tazverik:0"
  },
  {
    "id": 512,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 436,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 513,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 437,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 514,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 438,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 515,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 439,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 516,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 440,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 517,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 441,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 518,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 442,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 519,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 443,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 520,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 444,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 521,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 445,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 522,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 446,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 523,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 447,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 524,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 448,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 525,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 449,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 526,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 450,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 527,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 451,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 528,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 452,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 529,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 453,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 530,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 454,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 531,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 455,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 532,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 456,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 533,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 457,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 534,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.afinitor"
    ],
    "proposition_id": 458,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.afinitor:1"
  },
  {
    "id": 535,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.afinitor"
    ],
    "proposition_id": 459,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.afinitor:1"
  },
  {
    "id": 536,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.afinitor"
    ],
    "proposition_id": 460,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.afinitor:2"
  },
  {
    "id": 537,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.afinitor"
    ],
    "proposition_id": 461,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.afinitor:2"
  },
  {
    "id": 538,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.talzenna"
    ],
    "proposition_id": 462,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.talzenna:1"
  },
  {
    "id": 539,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tagrisso"
    ],
    "proposition_id": 304,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tagrisso:4"
  },
  {
    "id": 540,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.tagrisso"
    ],
    "proposition_id": 305,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tagrisso:4"
  },
  {
    "id": 541,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rybrevant"
    ],
    "proposition_id": 463,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rybrevant:2"
  },
  {
    "id": 542,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rybrevant"
    ],
    "proposition_id": 464,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rybrevant:2"
  },
  {
    "id": 543,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lazcluze"
    ],
    "proposition_id": 463,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lazcluze:0"
  },
  {
    "id": 544,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.lazcluze"
    ],
    "proposition_id": 464,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.lazcluze:0"
  },
  {
    "id": 545,
    "type": "Statement",
    "description": "The U.S. Food and Drug administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rybrevant"
    ],
    "proposition_id": 465,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rybrevant:3"
  },
  {
    "id": 546,
    "type": "Statement",
    "description": "The U.S. Food and Drug administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.rybrevant"
    ],
    "proposition_id": 466,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.rybrevant:3"
  },
  {
    "id": 547,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.elahere"
    ],
    "proposition_id": 467,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.elahere:0"
  },
  {
    "id": 548,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.elahere"
    ],
    "proposition_id": 468,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.elahere:0"
  },
  {
    "id": 549,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.elahere"
    ],
    "proposition_id": 469,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.elahere:0"
  },
  {
    "id": 550,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.ojemda"
    ],
    "proposition_id": 470,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ojemda:0"
  },
  {
    "id": 551,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.ojemda"
    ],
    "proposition_id": 471,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ojemda:0"
  },
  {
    "id": 552,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.ojemda"
    ],
    "proposition_id": 472,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ojemda:0"
  },
  {
    "id": 553,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.ojemda"
    ],
    "proposition_id": 473,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ojemda:0"
  },
  {
    "id": 554,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN\n(NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imfinzi"
    ],
    "proposition_id": 474,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imfinzi:2"
  },
  {
    "id": 555,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN\n(NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imfinzi"
    ],
    "proposition_id": 475,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imfinzi:2"
  },
  {
    "id": 556,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN\n(NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imfinzi"
    ],
    "proposition_id": 476,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imfinzi:2"
  },
  {
    "id": 557,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN\n(NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imfinzi"
    ],
    "proposition_id": 477,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imfinzi:2"
  },
  {
    "id": 558,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib in combination with cetuximab for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) and that continued approval for this indications may be contingent upon verification and description of a clinical benefit in confirmatory trials.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.krazati"
    ],
    "proposition_id": 478,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.krazati:1"
  },
  {
    "id": 559,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 479,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 560,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 480,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 561,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 481,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 562,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 482,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 563,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 483,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 564,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 484,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 565,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 485,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 566,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 486,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 567,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 487,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 568,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 488,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 569,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 489,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 570,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 490,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 571,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 491,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 572,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 492,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 573,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 493,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 574,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 494,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 575,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 495,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 576,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 496,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 577,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 497,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 578,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.voranigo"
    ],
    "proposition_id": 498,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.voranigo:0"
  },
  {
    "id": 579,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 499,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:2"
  },
  {
    "id": 580,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 500,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:2"
  },
  {
    "id": 581,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 501,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:2"
  },
  {
    "id": 582,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 502,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:2"
  },
  {
    "id": 583,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 503,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:2"
  },
  {
    "id": 584,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.kisqali"
    ],
    "proposition_id": 504,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.kisqali:2"
  },
  {
    "id": 585,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.opdivo"
    ],
    "proposition_id": 505,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.opdivo:0"
  },
  {
    "id": 586,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.opdivo"
    ],
    "proposition_id": 506,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.opdivo:0"
  },
  {
    "id": 587,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.opdivo"
    ],
    "proposition_id": 172,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.opdivo:2"
  },
  {
    "id": 588,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.opdivo"
    ],
    "proposition_id": 173,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.opdivo:2"
  },
  {
    "id": 589,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.opdivo"
    ],
    "proposition_id": 174,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.opdivo:2"
  },
  {
    "id": 591,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.",
    "contributions": [
      0,
      4
    ],
    "reportedIn": [
      "doc:fda.opdivo"
    ],
    "proposition_id": 507,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.opdivo:4"
  },
  {
    "id": 592,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to nivolumab as a single agent for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",
    "contributions": [
      0,
      4
    ],
    "reportedIn": [
      "doc:fda.opdivo"
    ],
    "proposition_id": 508,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.opdivo:3"
  },
  {
    "id": 593,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to nivolumab as a single agent for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",
    "contributions": [
      0,
      4
    ],
    "reportedIn": [
      "doc:fda.opdivo"
    ],
    "proposition_id": 509,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.opdivo:3"
  },
  {
    "id": 594,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.itovebi"
    ],
    "proposition_id": 510,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.itovebi:0"
  },
  {
    "id": 595,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.itovebi"
    ],
    "proposition_id": 511,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.itovebi:0"
  },
  {
    "id": 596,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.itovebi"
    ],
    "proposition_id": 512,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.itovebi:0"
  },
  {
    "id": 597,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive, as determined by an FDA-approved test. The package insert states that that eligible patients should have CLDN18.2 positive tumors, defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining. The package insert further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.vyloy"
    ],
    "proposition_id": 513,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.vyloy:0"
  },
  {
    "id": 598,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive, as determined by an FDA-approved test. The package insert states that that eligible patients should have CLDN18.2 positive tumors, defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining. The package insert further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.vyloy"
    ],
    "proposition_id": 514,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.vyloy:0"
  },
  {
    "id": 599,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.ziihera"
    ],
    "proposition_id": 515,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ziihera:0"
  },
  {
    "id": 600,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.ziihera"
    ],
    "proposition_id": 516,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ziihera:0"
  },
  {
    "id": 601,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.ziihera"
    ],
    "proposition_id": 517,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ziihera:0"
  },
  {
    "id": 602,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.bizengri"
    ],
    "proposition_id": 518,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.bizengri:0"
  },
  {
    "id": 603,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.bizengri"
    ],
    "proposition_id": 519,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.bizengri:1"
  },
  {
    "id": 604,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to ensartinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.ensacove"
    ],
    "proposition_id": 520,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ensacove:0"
  },
  {
    "id": 605,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Furthermore, it states that encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.braftovi"
    ],
    "proposition_id": 521,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.braftovi:3"
  },
  {
    "id": 606,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).",
    "contributions": [
      1,
      7
    ],
    "reportedIn": [
      "doc:fda.scemblix"
    ],
    "proposition_id": 522,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.scemblix:0"
  },
  {
    "id": 607,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to asciminib for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). The package insert states that this indication is approved under accelerated approval based on major molecular response rate and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.scemblix"
    ],
    "proposition_id": 522,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.scemblix:2"
  },
  {
    "id": 608,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imjudo"
    ],
    "proposition_id": 104,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imjudo:0"
  },
  {
    "id": 609,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imjudo"
    ],
    "proposition_id": 105,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imjudo:0"
  },
  {
    "id": 610,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imjudo"
    ],
    "proposition_id": 106,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imjudo:0"
  },
  {
    "id": 611,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imjudo"
    ],
    "proposition_id": 107,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imjudo:0"
  },
  {
    "id": 612,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.imjudo"
    ],
    "proposition_id": 108,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imjudo:0"
  },
  {
    "id": 613,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.revuforj"
    ],
    "proposition_id": 528,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.revuforj:0"
  },
  {
    "id": 614,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.revuforj"
    ],
    "proposition_id": 529,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.revuforj:0"
  },
  {
    "id": 615,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.revuforj"
    ],
    "proposition_id": 530,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.revuforj:0"
  },
  {
    "id": 616,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.",
    "contributions": [
      1
    ],
    "reportedIn": [
      "doc:fda.revuforj"
    ],
    "proposition_id": 531,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.revuforj:0"
  },
  {
    "id": 617,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "contributions": [
      0,
      3
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 7,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:0"
  },
  {
    "id": 618,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "contributions": [
      0,
      3
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 5,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:0"
  },
  {
    "id": 619,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "contributions": [
      0,
      3
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 3,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:0"
  },
  {
    "id": 620,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "contributions": [
      0,
      3
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 4,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:0"
  },
  {
    "id": 621,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "contributions": [
      0,
      3
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 792,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:0"
  },
  {
    "id": 622,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "contributions": [
      0,
      3
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 793,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:0"
  },
  {
    "id": 623,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "contributions": [
      0,
      3
    ],
    "reportedIn": [
      "doc:fda.verzenio"
    ],
    "proposition_id": 794,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.verzenio:0"
  },
  {
    "id": 624,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.",
    "contributions": [
      0,
      4
    ],
    "reportedIn": [
      "doc:fda.opdivo"
    ],
    "proposition_id": 169,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.opdivo:4"
  },
  {
    "id": 625,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The package insert instructs to select patients based on the presence of ROS1 rearrangements in tumor specimen(s).",
    "contributions": [
      6
    ],
    "reportedIn": [
      "doc:fda.ibtrozi"
    ],
    "proposition_id": 836,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.ibtrozi:0"
  },
  {
    "id": 626,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin, a c-Met-directed antibody and microtubule inhibitor conjugate, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).",
    "contributions": [
      6
    ],
    "reportedIn": [
      "doc:fda.emrelis"
    ],
    "proposition_id": 837,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.emrelis:0"
  },
  {
    "id": 627,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This approval is based on RAMP-201 (NCT04625270), an open-label, multicenter study that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC. The KRAS mutations identified by local testing were G12V (53%), G12D (35%), Q61H (3.5%), G12C (1.8%), G12R (1.8%), A146V (1.8%), and mutations not otherwise specified at G12x (1.8%) and on codon 12/13 (1.8%). 44% of patients responded (3.5% with complete response, 40% with partial response), and the package insert notes that the tumor KRAS mutations observed in the 25 responders were A146V, G12D, G12R, G12V, and Q61H.",
    "contributions": [
      6
    ],
    "reportedIn": [
      "doc:fda.avmapki-fakzynja"
    ],
    "proposition_id": 838,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.avmapki-fakzynja:0"
  },
  {
    "id": 628,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This approval is based on RAMP-201 (NCT04625270), an open-label, multicenter study that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC. The KRAS mutations identified by local testing were G12V (53%), G12D (35%), Q61H (3.5%), G12C (1.8%), G12R (1.8%), A146V (1.8%), and mutations not otherwise specified at G12x (1.8%) and on codon 12/13 (1.8%). 44% of patients responded (3.5% with complete response, 40% with partial response), and the package insert notes that the tumor KRAS mutations observed in the 25 responders were A146V, G12D, G12R, G12V, and Q61H.",
    "contributions": [
      6
    ],
    "reportedIn": [
      "doc:fda.avmapki-fakzynja"
    ],
    "proposition_id": 839,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.avmapki-fakzynja:0"
  },
  {
    "id": 629,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
    "contributions": [
      7
    ],
    "reportedIn": [
      "doc:fda.trisenox"
    ],
    "proposition_id": 840,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.trisenox:0"
  },
  {
    "id": 630,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
    "contributions": [
      7
    ],
    "reportedIn": [
      "doc:fda.trisenox"
    ],
    "proposition_id": 840,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.trisenox:1"
  },
  {
    "id": 631,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.tasigna"
    ],
    "proposition_id": 221,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tasigna:2"
  },
  {
    "id": 632,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "contributions": [
      0,
      7
    ],
    "reportedIn": [
      "doc:fda.tasigna"
    ],
    "proposition_id": 222,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tasigna:2"
  },
  {
    "id": 634,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to asciminib for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). The package insert states that this indication is approved under accelerated approval based on major molecular response rate and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      1,
      7
    ],
    "reportedIn": [
      "doc:fda.scemblix"
    ],
    "proposition_id": 29,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.scemblix:2"
  },
  {
    "id": 635,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin, and then as a single agent for the treatment of adult patients with resectable locally advanced head and neck squamous cell cancer (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) >= 1], as determined by an FDA-approved test.",
    "contributions": [
      8
    ],
    "reportedIn": [
      "doc:fda.keytruda"
    ],
    "proposition_id": 320,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.keytruda:16"
  },
  {
    "id": 636,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to datopotamab deruxtecan-dlnk for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. This approval is based on two clinical studies: TROPION-Lung05 and TROPION-Lung01, where efficacy was assessed in 114 patients with EGFR-mutated NSCLC. Fifty-three percent (53%) of patients had exon 19 deletions, 34% had exon 21 L858R mutations, 28% had T790M mutations, 2.6% had exon 20 insertion mutations, and 14% had other EGFR mutations.",
    "contributions": [
      9
    ],
    "reportedIn": [
      "doc:fda.datroway"
    ],
    "proposition_id": 849,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.datroway:0"
  },
  {
    "id": 637,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to datopotamab deruxtecan-dlnk for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. This approval is based on two clinical studies: TROPION-Lung05 and TROPION-Lung01, where efficacy was assessed in 114 patients with EGFR-mutated NSCLC. Fifty-three percent (53%) of patients had exon 19 deletions, 34% had exon 21 L858R mutations, 28% had T790M mutations, 2.6% had exon 20 insertion mutations, and 14% had other EGFR mutations.",
    "contributions": [
      9
    ],
    "reportedIn": [
      "doc:fda.datroway"
    ],
    "proposition_id": 850,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.datroway:0"
  },
  {
    "id": 638,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to datopotamab deruxtecan-dlnk for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. This approval is based on two clinical studies: TROPION-Lung05 and TROPION-Lung01, where efficacy was assessed in 114 patients with EGFR-mutated NSCLC. Fifty-three percent (53%) of patients had exon 19 deletions, 34% had exon 21 L858R mutations, 28% had T790M mutations, 2.6% had exon 20 insertion mutations, and 14% had other EGFR mutations.",
    "contributions": [
      9
    ],
    "reportedIn": [
      "doc:fda.datroway"
    ],
    "proposition_id": 851,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.datroway:0"
  },
  {
    "id": 639,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to datopotamab deruxtecan-dlnk for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. This approval is based on two clinical studies: TROPION-Lung05 and TROPION-Lung01, where efficacy was assessed in 114 patients with EGFR-mutated NSCLC. Fifty-three percent (53%) of patients had exon 19 deletions, 34% had exon 21 L858R mutations, 28% had T790M mutations, 2.6% had exon 20 insertion mutations, and 14% had other EGFR mutations.",
    "contributions": [
      9
    ],
    "reportedIn": [
      "doc:fda.datroway"
    ],
    "proposition_id": 852,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.datroway:0"
  },
  {
    "id": 640,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to datopotamab deruxtecan-dlnk for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. This approval is based on two clinical studies: TROPION-Lung05 and TROPION-Lung01, where efficacy was assessed in 114 patients with EGFR-mutated NSCLC. Fifty-three percent (53%) of patients had exon 19 deletions, 34% had exon 21 L858R mutations, 28% had T790M mutations, 2.6% had exon 20 insertion mutations, and 14% had other EGFR mutations.",
    "contributions": [
      9
    ],
    "reportedIn": [
      "doc:fda.datroway"
    ],
    "proposition_id": 853,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.datroway:0"
  },
  {
    "id": 641,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to datopotamab deruxtecan-dlnk for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.",
    "contributions": [
      10
    ],
    "reportedIn": [
      "doc:fda.datroway"
    ],
    "proposition_id": 854,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.datroway:1"
  },
  {
    "id": 642,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to datopotamab deruxtecan-dlnk for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.",
    "contributions": [
      10
    ],
    "reportedIn": [
      "doc:fda.datroway"
    ],
    "proposition_id": 855,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.datroway:1"
  },
  {
    "id": 643,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to datopotamab deruxtecan-dlnk for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.",
    "contributions": [
      10
    ],
    "reportedIn": [
      "doc:fda.datroway"
    ],
    "proposition_id": 856,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.datroway:1"
  },
  {
    "id": 644,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to sunvozertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "contributions": [
      11
    ],
    "reportedIn": [
      "doc:fda.zegfrovy"
    ],
    "proposition_id": 857,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.zegfrovy:0"
  },
  {
    "id": 645,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to zongertinib for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contributions": [
      12
    ],
    "reportedIn": [
      "doc:fda.hernexeos"
    ],
    "proposition_id": 858,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.hernexeos:0"
  },
  {
    "id": 646,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.adcetris"
    ],
    "proposition_id": 532,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.adcetris:0"
  },
  {
    "id": 647,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ Hodgkin lymphoma (HL) at increased risk of relapase or progression following autologous stemc ell transplant (ASCT).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.adcetris"
    ],
    "proposition_id": 533,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.adcetris:1"
  },
  {
    "id": 648,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) either following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.adcetris"
    ],
    "proposition_id": 533,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.adcetris:2"
  },
  {
    "id": 649,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.adcetris"
    ],
    "proposition_id": 534,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.adcetris:3"
  },
  {
    "id": 650,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.afinitor"
    ],
    "proposition_id": 131,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.afinitor:0"
  },
  {
    "id": 651,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.afinitor"
    ],
    "proposition_id": 132,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.afinitor:0"
  },
  {
    "id": 652,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.afinitor"
    ],
    "proposition_id": 133,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.afinitor:0"
  },
  {
    "id": 653,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.akeega"
    ],
    "proposition_id": 537,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.akeega:0"
  },
  {
    "id": 654,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.akeega"
    ],
    "proposition_id": 538,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.akeega:0"
  },
  {
    "id": 655,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.akeega"
    ],
    "proposition_id": 539,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.akeega:0"
  },
  {
    "id": 656,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.akeega"
    ],
    "proposition_id": 540,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.akeega:0"
  },
  {
    "id": 657,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.alecensa"
    ],
    "proposition_id": 22,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.alecensa:0"
  },
  {
    "id": 658,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.alecensa"
    ],
    "proposition_id": 22,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.alecensa:1"
  },
  {
    "id": 659,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the adjuvant treatment following complete tumor resection for adult patients with ALK-positive non-small cell lung cancer (NSCLC) at high risk of recurrence.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.alecensa"
    ],
    "proposition_id": 22,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.alecensa:2"
  },
  {
    "id": 660,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who were previously not treated with an ALK inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.alunbrig"
    ],
    "proposition_id": 50,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.alunbrig:0"
  },
  {
    "id": 661,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.alunbrig"
    ],
    "proposition_id": 50,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.alunbrig:1"
  },
  {
    "id": 662,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized bevacizumab in combination with erlotinib for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating variants. This indication is based on JO25567, a randomized, open-label, multi-centre phase 2 study that defined EGFR activating variants as either exon 19 deletions or exon 21 p.L858R.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.avastin"
    ],
    "proposition_id": 541,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.avastin:0"
  },
  {
    "id": 663,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized bevacizumab in combination with erlotinib for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating variants. This indication is based on JO25567, a randomized, open-label, multi-centre phase 2 study that defined EGFR activating variants as either exon 19 deletions or exon 21 p.L858R.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.avastin"
    ],
    "proposition_id": 542,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.avastin:0"
  },
  {
    "id": 664,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized avapritinib as a monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring the platelet-derived growth factor receptor alpha (PDGFRA) p.D842V variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.ayvakyt"
    ],
    "proposition_id": 40,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.ayvakyt:0"
  },
  {
    "id": 665,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Besponsa (inotuzumab ozogamicin) as a monotherapy for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). Adult patients with Philidelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor (TKI).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.besponsa"
    ],
    "proposition_id": 543,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.besponsa:0"
  },
  {
    "id": 666,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Besponsa (inotuzumab ozogamicin) as a monotherapy for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). Adult patients with Philidelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor (TKI).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.besponsa"
    ],
    "proposition_id": 168,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.besponsa:0"
  },
  {
    "id": 667,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.blincyto"
    ],
    "proposition_id": 45,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.blincyto:0"
  },
  {
    "id": 668,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.blincyto"
    ],
    "proposition_id": 46,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.blincyto:0"
  },
  {
    "id": 669,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with Philadelphia chromosome negative CD19 positive B-cell precusor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.blincyto"
    ],
    "proposition_id": 46,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.blincyto:1"
  },
  {
    "id": 670,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 year or older with Philidelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplants.",
    "contributions": [
      13,
      14
    ],
    "reportedIn": [
      "doc:ema.blincyto"
    ],
    "proposition_id": 46,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.blincyto:2"
  },
  {
    "id": 671,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 year or older with high-risk first relapsed Philidelphia chromosome negative CD19 positive B-cell precursor ALL as part of the consolidation therapy.",
    "contributions": [
      13,
      14
    ],
    "reportedIn": [
      "doc:ema.blincyto"
    ],
    "proposition_id": 46,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.blincyto:3"
  },
  {
    "id": 672,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).",
    "contributions": [
      13,
      16
    ],
    "reportedIn": [
      "doc:ema.bosulif"
    ],
    "proposition_id": 47,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.bosulif:0"
  },
  {
    "id": 673,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with chronic phase, accelerated phase, and blast phase Ph+ CML previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are no considered appropriate treatment options.",
    "contributions": [
      13,
      16
    ],
    "reportedIn": [
      "doc:ema.bosulif"
    ],
    "proposition_id": 47,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.bosulif:1"
  },
  {
    "id": 674,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.braftovi"
    ],
    "proposition_id": 41,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.braftovi:0"
  },
  {
    "id": 675,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.braftovi"
    ],
    "proposition_id": 42,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.braftovi:0"
  },
  {
    "id": 676,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF p.V600E variant, who have received prior systemic therapy. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.braftovi"
    ],
    "proposition_id": 81,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.braftovi:1"
  },
  {
    "id": 677,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.braftovi"
    ],
    "proposition_id": 43,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.braftovi:2"
  },
  {
    "id": 678,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vandetanib for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is indicated in adults, children, and adolescents aged 5 years and older.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.caprelsa"
    ],
    "proposition_id": 547,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.caprelsa:0"
  },
  {
    "id": 679,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.cotellic"
    ],
    "proposition_id": 82,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.cotellic:0"
  },
  {
    "id": 680,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.cotellic"
    ],
    "proposition_id": 83,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.cotellic:0"
  },
  {
    "id": 681,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ramucirumab in combination with erlotinib as a first-line treatment for adult patients with metastatic non-small cell lung cancer with activating EGFR variants.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.cyramza"
    ],
    "proposition_id": 548,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.cyramza:0"
  },
  {
    "id": 682,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.taxotere"
    ],
    "proposition_id": 549,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.taxotere:0"
  },
  {
    "id": 683,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.taxotere"
    ],
    "proposition_id": 550,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.taxotere:0"
  },
  {
    "id": 684,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimes.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 420,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:0"
  },
  {
    "id": 685,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimes.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 551,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:0"
  },
  {
    "id": 686,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. For the purposes of this indication, HER2-low is defined as a score of IHC 1+ or IHC 2+/ISH-, as assessed by a CE-marked IVD medical device or alternative valid test.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 421,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:1"
  },
  {
    "id": 687,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) variant and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 552,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:2"
  },
  {
    "id": 688,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) variant and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 422,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:2"
  },
  {
    "id": 689,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 423,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:3"
  },
  {
    "id": 690,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 553,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:3"
  },
  {
    "id": 691,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized cetuximab as a single agent for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.erbitux"
    ],
    "proposition_id": 554,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.erbitux:0"
  },
  {
    "id": 692,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized cetuximab in combination with irinotecan-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.erbitux"
    ],
    "proposition_id": 555,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.erbitux:1"
  },
  {
    "id": 693,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized cetuximab in combination with FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) for the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.erbitux"
    ],
    "proposition_id": 556,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.erbitux:2"
  },
  {
    "id": 694,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized fulvestrant as a monotherapy for the treatment of patients who are postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer. These patients should not have been previously treated with endocrine therapy, or have had disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.faslodex"
    ],
    "proposition_id": 137,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.faslodex:0"
  },
  {
    "id": 695,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.faslodex"
    ],
    "proposition_id": 143,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.faslodex:1"
  },
  {
    "id": 696,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.faslodex"
    ],
    "proposition_id": 144,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.faslodex:1"
  },
  {
    "id": 697,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.faslodex"
    ],
    "proposition_id": 145,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.faslodex:1"
  },
  {
    "id": 698,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pralsetinib as a monotherapy treatment for adult patients with RET fusion-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with a RET inhibitor.",
    "contributions": [
      13,
      18
    ],
    "reportedIn": [
      "doc:ema.gavreto"
    ],
    "proposition_id": 364,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.gavreto:0",
    "status": "Withdrawn"
  },
  {
    "id": 699,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized gefitinib as a monotherapy treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating variants of EGFR-TK.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.iressa"
    ],
    "proposition_id": 559,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.iressa:0"
  },
  {
    "id": 700,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized afatinib as a monotherapy indicated for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR variants.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.giotrif"
    ],
    "proposition_id": 560,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.giotrif:0"
  },
  {
    "id": 701,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 418,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:0"
  },
  {
    "id": 702,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 561,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:1"
  },
  {
    "id": 703,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 549,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:2"
  },
  {
    "id": 704,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 562,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:3"
  },
  {
    "id": 705,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 418,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:4"
  },
  {
    "id": 706,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 561,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:5"
  },
  {
    "id": 707,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 549,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:5"
  },
  {
    "id": 708,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin for the treatment of adult patients with HER2 positive early breast cancer (EBC). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 563,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:6"
  },
  {
    "id": 709,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) whose tumors are locally advanced (including inflammatory) disease or > 2 cm in diameter. This indication is based on the multicenter randomized trial MO16432 which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 564,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:7"
  },
  {
    "id": 710,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 565,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:0"
  },
  {
    "id": 711,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 566,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:1"
  },
  {
    "id": 712,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 550,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:2"
  },
  {
    "id": 713,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 567,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:3"
  },
  {
    "id": 714,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 565,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:4"
  },
  {
    "id": 715,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 566,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:5"
  },
  {
    "id": 716,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 550,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:5"
  },
  {
    "id": 717,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin for the treatment of adult patients with HER2 positive early breast cancer (EBC). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 568,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:6"
  },
  {
    "id": 718,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) whose tumors are locally advanced (including inflammatory) disease or > 2 cm in diameter. This indication is based on the multicenter randomized trial MO16432 which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 569,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:7"
  },
  {
    "id": 719,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 570,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:8"
  },
  {
    "id": 720,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 571,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:8"
  },
  {
    "id": 721,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 572,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:8"
  },
  {
    "id": 722,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.herceptin"
    ],
    "proposition_id": 573,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.herceptin:8"
  },
  {
    "id": 723,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.ibrance"
    ],
    "proposition_id": 311,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.ibrance:0"
  },
  {
    "id": 724,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.ibrance"
    ],
    "proposition_id": 312,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.ibrance:0"
  },
  {
    "id": 725,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.ibrance"
    ],
    "proposition_id": 313,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.ibrance:0"
  },
  {
    "id": 726,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.ibrance"
    ],
    "proposition_id": 143,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.ibrance:1"
  },
  {
    "id": 727,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.ibrance"
    ],
    "proposition_id": 144,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.ibrance:1"
  },
  {
    "id": 728,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.ibrance"
    ],
    "proposition_id": 145,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.ibrance:1"
  },
  {
    "id": 729,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 578,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:0"
  },
  {
    "id": 730,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 578,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:1"
  },
  {
    "id": 731,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 579,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:2"
  },
  {
    "id": 732,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized imatinib as a monotherapy treatment for adult patients with relapased or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 579,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:3"
  },
  {
    "id": 733,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 161,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:4"
  },
  {
    "id": 734,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 162,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:4"
  },
  {
    "id": 735,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 580,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:4"
  },
  {
    "id": 736,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 581,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:4"
  },
  {
    "id": 737,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with a FIP1L1::PDGFRA rearrangement.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 164,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:5"
  },
  {
    "id": 738,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 165,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:6"
  },
  {
    "id": 739,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD 117) positive gastrointestinal stromal tumors (GIST). Patients who have a low or very low risk of recurrence should not received adjuvant treatment.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 165,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:7"
  },
  {
    "id": 740,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the p.T315I variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.iclusig"
    ],
    "proposition_id": 363,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.iclusig:0"
  },
  {
    "id": 741,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.iclusig"
    ],
    "proposition_id": 582,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.iclusig:1"
  },
  {
    "id": 742,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.iclusig"
    ],
    "proposition_id": 583,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.iclusig:1"
  },
  {
    "id": 743,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized durvalumab as a monotherapy for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumors express PD-L1 on >= 1% of tumor cells and whose disease has not progressed following platinum-based chemoradiation therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.imfinzi"
    ],
    "proposition_id": 584,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.imfinzi:0"
  },
  {
    "id": 744,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) and no sensitizing EGFR mutations or ALK positive mutations. This indication is POSEIDON (NCT03164616), a randomized, multicenter, active-controlled, and open-label study where the specific chemotherapy regime used was based on the histology of the patient's NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.imfinzi"
    ],
    "proposition_id": 585,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.imfinzi:1"
  },
  {
    "id": 745,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.imfinzi"
    ],
    "proposition_id": 109,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.imfinzi:2"
  },
  {
    "id": 746,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.imfinzi"
    ],
    "proposition_id": 586,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.imfinzi:2"
  },
  {
    "id": 747,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) and no sensitizing EGFR mutations or ALK positive mutations. This indication is POSEIDON (NCT03164616), a randomized, multicenter, active-controlled, and open-label study where the specific chemotherapy regime used was based on the histology of the patient's NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.imjudo"
    ],
    "proposition_id": 585,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.imjudo:0"
  },
  {
    "id": 748,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.jemperli"
    ],
    "proposition_id": 101,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.jemperli:0",
    "status": "Deprecated"
  },
  {
    "id": 749,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.jemperli"
    ],
    "proposition_id": 100,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.jemperli:0",
    "status": "Deprecated"
  },
  {
    "id": 750,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.jemperli"
    ],
    "proposition_id": 587,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.jemperli:1"
  },
  {
    "id": 751,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.jemperli"
    ],
    "proposition_id": 102,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.jemperli:1"
  },
  {
    "id": 752,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 588,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:0"
  },
  {
    "id": 753,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 589,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:0"
  },
  {
    "id": 754,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 316,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:1"
  },
  {
    "id": 755,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 317,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:1"
  },
  {
    "id": 756,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 592,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:1"
  },
  {
    "id": 757,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 593,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:1"
  },
  {
    "id": 758,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 594,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:1"
  },
  {
    "id": 759,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung carcinoma whose tumors express PD-L1 with a >= 1% tumor proportion score (TPS) and who have recieved at least one prior chemotherapy regime. Patients with EGFR or ALK positive tumor mutations should also have received targeted therapy before receiving pembrolizumab.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 319,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:2"
  },
  {
    "id": 760,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 with a combined positive score (CPS) >= 10.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 595,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:3"
  },
  {
    "id": 761,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 320,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:4"
  },
  {
    "id": 762,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 596,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:4"
  },
  {
    "id": 763,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 597,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:4"
  },
  {
    "id": 764,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma whose tumors express PD-L1 with a tumor proportion score >= 50% and who have progressed on or after platinum-containing chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 598,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:5"
  },
  {
    "id": 765,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer as a first line-treatment for metastatic colorectal cancer or treatment of unresectable or metastatic colorectal cancer after previously fluoropryimidine-based combination therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 324,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:6"
  },
  {
    "id": 766,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer as a first line-treatment for metastatic colorectal cancer or treatment of unresectable or metastatic colorectal cancer after previously fluoropryimidine-based combination therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 323,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:6"
  },
  {
    "id": 767,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 343,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:7"
  },
  {
    "id": 768,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 599,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:7"
  },
  {
    "id": 769,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 600,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:8"
  },
  {
    "id": 770,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 601,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:8"
  },
  {
    "id": 771,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 602,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:8"
  },
  {
    "id": 772,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 603,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:8"
  },
  {
    "id": 773,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 604,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:8"
  },
  {
    "id": 774,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 605,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:8"
  },
  {
    "id": 775,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adult patients with locally advanced unresectable or metastatic esophageal carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 10.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 606,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:9"
  },
  {
    "id": 776,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adult patients with locally advanced unresectable or metastatic esophageal carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 10.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 607,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:9"
  },
  {
    "id": 777,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then continued as a monotherapy for the adjuvant treatment after surgery, of adult patients with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 608,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:10"
  },
  {
    "id": 778,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 346,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:11"
  },
  {
    "id": 779,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 609,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:11"
  },
  {
    "id": 780,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 347,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:11"
  },
  {
    "id": 781,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy and with or without bevacizumab for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1. This indication is based on KEYNOTE-826, a multicenter, randomized, double-blind, and placebo-controlled study that studied the efficacy of pembrolizumab in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab in 617 patients meeting this indication's clinical criteria.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 335,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:12"
  },
  {
    "id": 782,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy and with or without bevacizumab for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1. This indication is based on KEYNOTE-826, a multicenter, randomized, double-blind, and placebo-controlled study that studied the efficacy of pembrolizumab in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab in 617 patients meeting this indication's clinical criteria.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 337,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:12"
  },
  {
    "id": 783,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 325,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:13"
  },
  {
    "id": 784,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 610,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:13"
  },
  {
    "id": 785,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 611,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:14"
  },
  {
    "id": 786,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.keytruda"
    ],
    "proposition_id": 612,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.keytruda:14"
  },
  {
    "id": 787,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.kadcyla"
    ],
    "proposition_id": 20,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kadcyla:0"
  },
  {
    "id": 788,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.kadcyla"
    ],
    "proposition_id": 613,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kadcyla:0"
  },
  {
    "id": 789,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.kadcyla"
    ],
    "proposition_id": 20,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kadcyla:1"
  },
  {
    "id": 790,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.kadcyla"
    ],
    "proposition_id": 613,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kadcyla:1"
  },
  {
    "id": 791,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.kisqali"
    ],
    "proposition_id": 375,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kisqali:0"
  },
  {
    "id": 792,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.kisqali"
    ],
    "proposition_id": 376,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kisqali:0"
  },
  {
    "id": 793,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.kisqali"
    ],
    "proposition_id": 377,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kisqali:0"
  },
  {
    "id": 794,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.kisqali"
    ],
    "proposition_id": 140,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kisqali:0"
  },
  {
    "id": 795,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.kisqali"
    ],
    "proposition_id": 141,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kisqali:0"
  },
  {
    "id": 796,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.kisqali"
    ],
    "proposition_id": 142,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kisqali:0"
  },
  {
    "id": 797,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized adagrasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and disease progression after at least one prior systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.krazati"
    ],
    "proposition_id": 19,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.krazati:0"
  },
  {
    "id": 798,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized cemiplimab as a monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in >= 50% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.libtayo"
    ],
    "proposition_id": 618,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.libtayo:0"
  },
  {
    "id": 799,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with NSCLC expressing PD-L1 (in >= 1% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC. This indication is based on Study 16113, a randomized, multi-center, double-blind, active-controlled trial. The chemotherapy used in this study consisted of either carboplatin or cisplatin in combination with paclitaxel or pemetrexed.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.libtayo"
    ],
    "proposition_id": 619,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.libtayo:1"
  },
  {
    "id": 800,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized lorlatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lorviqua"
    ],
    "proposition_id": 203,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lorviqua:0"
  },
  {
    "id": 801,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized lorlatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lorviqua"
    ],
    "proposition_id": 203,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lorviqua:1"
  },
  {
    "id": 802,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized sotorasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and who have progressed after at least one prior line of systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lumykras"
    ],
    "proposition_id": 411,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lumykras:0"
  },
  {
    "id": 803,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 231,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:0"
  },
  {
    "id": 804,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 235,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:0"
  },
  {
    "id": 805,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 239,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:0"
  },
  {
    "id": 806,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 232,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:0"
  },
  {
    "id": 807,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 236,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:0"
  },
  {
    "id": 808,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 240,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:0"
  },
  {
    "id": 809,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 233,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:0"
  },
  {
    "id": 810,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 237,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:0"
  },
  {
    "id": 811,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 241,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:0"
  },
  {
    "id": 812,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 234,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:0"
  },
  {
    "id": 813,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 238,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:0"
  },
  {
    "id": 814,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 242,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:0"
  },
  {
    "id": 815,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 243,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 816,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 248,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 817,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 253,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 818,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 244,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 819,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 249,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 820,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 254,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 821,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 245,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 822,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 250,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 823,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 255,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 824,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 246,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 825,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 251,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 826,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 256,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 827,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 247,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 828,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 252,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 829,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 257,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:1"
  },
  {
    "id": 830,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 258,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:2"
  },
  {
    "id": 831,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as both a monotherapy and in combination with endocrine for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Lynparza's product information cites the OlympiA trial, where olaparib was compared against placebo for the treatment of patients with germline BRCA1/2 mutated and HER2-negative high risk early breast cancer.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 258,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:3"
  },
  {
    "id": 832,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 259,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:2"
  },
  {
    "id": 833,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as both a monotherapy and in combination with endocrine for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Lynparza's product information cites the OlympiA trial, where olaparib was compared against placebo for the treatment of patients with germline BRCA1/2 mutated and HER2-negative high risk early breast cancer.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 259,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:3"
  },
  {
    "id": 834,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 260,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:4"
  },
  {
    "id": 835,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 261,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:4"
  },
  {
    "id": 836,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 263,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:5"
  },
  {
    "id": 837,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 265,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:5"
  },
  {
    "id": 838,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 264,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:5"
  },
  {
    "id": 839,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 266,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:5"
  },
  {
    "id": 840,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with durvalumab for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lynparza"
    ],
    "proposition_id": 620,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lynparza:6"
  },
  {
    "id": 841,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has given futibatinib conditional market authorization as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement that have progressed after at least one line of prior systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lytgobi"
    ],
    "proposition_id": 146,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lytgobi:0"
  },
  {
    "id": 842,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has given futibatinib conditional market authorization as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement that have progressed after at least one line of prior systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.lytgobi"
    ],
    "proposition_id": 621,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lytgobi:0"
  },
  {
    "id": 843,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mabthera"
    ],
    "proposition_id": 622,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mabthera:0"
  },
  {
    "id": 844,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mabthera"
    ],
    "proposition_id": 380,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mabthera:0"
  },
  {
    "id": 845,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mabthera"
    ],
    "proposition_id": 624,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mabthera:1"
  },
  {
    "id": 846,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mabthera"
    ],
    "proposition_id": 625,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mabthera:1"
  },
  {
    "id": 847,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mabthera"
    ],
    "proposition_id": 626,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mabthera:1"
  },
  {
    "id": 848,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mekinist"
    ],
    "proposition_id": 416,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mekinist:0"
  },
  {
    "id": 849,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mekinist"
    ],
    "proposition_id": 417,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mekinist:0"
  },
  {
    "id": 850,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mekinist"
    ],
    "proposition_id": 89,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mekinist:0"
  },
  {
    "id": 851,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 variant, following complete resection.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mekinist"
    ],
    "proposition_id": 89,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mekinist:1"
  },
  {
    "id": 852,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mekinist"
    ],
    "proposition_id": 90,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mekinist:0"
  },
  {
    "id": 853,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 variant, following complete resection.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mekinist"
    ],
    "proposition_id": 90,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mekinist:1"
  },
  {
    "id": 854,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mekinist"
    ],
    "proposition_id": 91,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mekinist:2"
  },
  {
    "id": 855,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mekinist"
    ],
    "proposition_id": 627,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mekinist:2"
  },
  {
    "id": 856,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mektovi"
    ],
    "proposition_id": 41,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mektovi:0"
  },
  {
    "id": 857,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mektovi"
    ],
    "proposition_id": 42,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mektovi:0"
  },
  {
    "id": 858,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mektovi"
    ],
    "proposition_id": 43,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mektovi:1"
  },
  {
    "id": 859,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized gemtuzumab ozogamicin in combination with cytarabine and daunorubicin for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukaemia (APL).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.mylotarg"
    ],
    "proposition_id": 628,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.mylotarg:0"
  },
  {
    "id": 860,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.nerlynx"
    ],
    "proposition_id": 629,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.nerlynx:0"
  },
  {
    "id": 861,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.nerlynx"
    ],
    "proposition_id": 630,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.nerlynx:0"
  },
  {
    "id": 862,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.nerlynx"
    ],
    "proposition_id": 631,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.nerlynx:0"
  },
  {
    "id": 863,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.nerlynx"
    ],
    "proposition_id": 632,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.nerlynx:0"
  },
  {
    "id": 864,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.nerlynx"
    ],
    "proposition_id": 633,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.nerlynx:0"
  },
  {
    "id": 865,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.nerlynx"
    ],
    "proposition_id": 634,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.nerlynx:0"
  },
  {
    "id": 866,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 172,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:0"
  },
  {
    "id": 867,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 173,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:0"
  },
  {
    "id": 868,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 174,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:0"
  },
  {
    "id": 869,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 638,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:1"
  },
  {
    "id": 870,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 639,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:1"
  },
  {
    "id": 871,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 640,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:1"
  },
  {
    "id": 872,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab as a monotherapy for the adjuvant treatment of adult patients with muscle invasive urothelial carcinoma (MIUC) with tumor cell PD-L1 expression >= 1%, who are at high risk of recurrence after undergoing radical resection of MIUC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 641,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:2"
  },
  {
    "id": 873,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 169,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:3"
  },
  {
    "id": 874,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 507,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:3"
  },
  {
    "id": 875,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 642,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:4"
  },
  {
    "id": 876,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable, advanced, or recurrent metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%. This indication is based on CA209648, a randomized, active-controlled, and open-label study where the choice of chemotherapy was fluorouracil and cisplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 643,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:5"
  },
  {
    "id": 877,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 644,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:6"
  },
  {
    "id": 878,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 645,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:6"
  },
  {
    "id": 879,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 646,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:6"
  },
  {
    "id": 880,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 647,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:6"
  },
  {
    "id": 881,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 648,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:6"
  },
  {
    "id": 882,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 649,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:6"
  },
  {
    "id": 883,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Opdualag (relatlimab / nivolumab) for the first-line treatment of adults and adolescents 12 years of age and older with advanced (unresectable or metastatic) melanoma with tumor cell PD-L1 expression < 1%.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.opdualag"
    ],
    "proposition_id": 650,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdualag:0"
  },
  {
    "id": 884,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized elacestrant for the treatment of postmenopausal women and men with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.orserdu"
    ],
    "proposition_id": 110,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.orserdu:0"
  },
  {
    "id": 885,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.pemazyre"
    ],
    "proposition_id": 651,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.pemazyre:0"
  },
  {
    "id": 886,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.pemazyre"
    ],
    "proposition_id": 652,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.pemazyre:0"
  },
  {
    "id": 887,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.perjeta"
    ],
    "proposition_id": 352,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.perjeta:0"
  },
  {
    "id": 888,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.perjeta"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.perjeta:0"
  },
  {
    "id": 889,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.perjeta"
    ],
    "proposition_id": 355,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.perjeta:1"
  },
  {
    "id": 890,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.perjeta"
    ],
    "proposition_id": 356,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.perjeta:1"
  },
  {
    "id": 891,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.perjeta"
    ],
    "proposition_id": 357,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.perjeta:1"
  },
  {
    "id": 892,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.perjeta"
    ],
    "proposition_id": 358,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.perjeta:1"
  },
  {
    "id": 893,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.perjeta"
    ],
    "proposition_id": 360,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.perjeta:1"
  },
  {
    "id": 894,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.perjeta"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.perjeta:2"
  },
  {
    "id": 895,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.phesgo"
    ],
    "proposition_id": 352,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.phesgo:0"
  },
  {
    "id": 896,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.phesgo"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.phesgo:0"
  },
  {
    "id": 897,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.phesgo"
    ],
    "proposition_id": 353,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.phesgo:1"
  },
  {
    "id": 898,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.phesgo"
    ],
    "proposition_id": 354,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.phesgo:1"
  },
  {
    "id": 899,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.phesgo"
    ],
    "proposition_id": 355,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.phesgo:1"
  },
  {
    "id": 900,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.phesgo"
    ],
    "proposition_id": 356,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.phesgo:1"
  },
  {
    "id": 901,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.phesgo"
    ],
    "proposition_id": 357,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.phesgo:1"
  },
  {
    "id": 902,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.phesgo"
    ],
    "proposition_id": 358,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.phesgo:1"
  },
  {
    "id": 903,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.phesgo"
    ],
    "proposition_id": 360,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.phesgo:1"
  },
  {
    "id": 904,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.phesgo"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.phesgo:2"
  },
  {
    "id": 905,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.piqray"
    ],
    "proposition_id": 653,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.piqray:0"
  },
  {
    "id": 906,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.piqray"
    ],
    "proposition_id": 654,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.piqray:0"
  },
  {
    "id": 907,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.piqray"
    ],
    "proposition_id": 655,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.piqray:0"
  },
  {
    "id": 908,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive non-small cell lung cancer not previously treated with a RET inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.retsevmo"
    ],
    "proposition_id": 407,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.retsevmo:0"
  },
  {
    "id": 909,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.retsevmo"
    ],
    "proposition_id": 656,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.retsevmo:1"
  },
  {
    "id": 910,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET-mutant medullary thyroid cancer. This indication is based on LIBRETTO-001 (a phase 1/2, multicenter, open-label, single-arm clinical study), where the most common variant was p.M918T, followed by extracelluar cysteine mutations.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.retsevmo"
    ],
    "proposition_id": 657,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.retsevmo:2"
  },
  {
    "id": 911,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.retsevmo"
    ],
    "proposition_id": 410,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.retsevmo:3"
  },
  {
    "id": 912,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized lenalidomide for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermdeiate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.revlimid"
    ],
    "proposition_id": 658,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.revlimid:0"
  },
  {
    "id": 913,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.rozlytrek"
    ],
    "proposition_id": 120,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rozlytrek:0"
  },
  {
    "id": 914,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.rozlytrek"
    ],
    "proposition_id": 121,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rozlytrek:1"
  },
  {
    "id": 915,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.rozlytrek"
    ],
    "proposition_id": 122,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rozlytrek:1"
  },
  {
    "id": 916,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.rozlytrek"
    ],
    "proposition_id": 123,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rozlytrek:1"
  },
  {
    "id": 917,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized midostaurin in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintence therapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive. Midostaurin's product information further states that AML patients must have confirmation of the FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.rydapt"
    ],
    "proposition_id": 208,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rydapt:0"
  },
  {
    "id": 918,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.scemblix"
    ],
    "proposition_id": 659,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.scemblix:0"
  },
  {
    "id": 919,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF p.V600E variant who require systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.spexotras"
    ],
    "proposition_id": 94,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.spexotras:0"
  },
  {
    "id": 920,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF p.V600E variant who have received at least one prior radiation and/or chemotherapy treatment.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.spexotras"
    ],
    "proposition_id": 660,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.spexotras:1"
  },
  {
    "id": 921,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.sprycel"
    ],
    "proposition_id": 661,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.sprycel:0"
  },
  {
    "id": 922,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.sprycel"
    ],
    "proposition_id": 662,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.sprycel:1"
  },
  {
    "id": 923,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.sprycel"
    ],
    "proposition_id": 661,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.sprycel:1"
  },
  {
    "id": 924,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase (Ph+ CML-CP) or Ph+CML-CP with resistant or intolerant to prior therapy including imatinib.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.sprycel"
    ],
    "proposition_id": 661,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.sprycel:2"
  },
  {
    "id": 925,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia acute lymphoblastic leukemia (ALL) in combination with chemotherapy. The product information for this indication further states that his indication is based on a multicenter, historically-controlled phase 2 study that followed the chemotherapy regime detailed in another clinical trial, AIEOP-BFM ALL 2000 (chemotherapeutic standard multi-agent chemotherapy protocol).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.sprycel"
    ],
    "proposition_id": 662,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.sprycel:3"
  },
  {
    "id": 926,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tabrecta"
    ],
    "proposition_id": 73,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tabrecta:0"
  },
  {
    "id": 927,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tabrecta"
    ],
    "proposition_id": 74,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tabrecta:0"
  },
  {
    "id": 928,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tafinlar"
    ],
    "proposition_id": 88,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tafinlar:0"
  },
  {
    "id": 929,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tafinlar"
    ],
    "proposition_id": 663,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tafinlar:0"
  },
  {
    "id": 930,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tafinlar"
    ],
    "proposition_id": 89,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tafinlar:0"
  },
  {
    "id": 931,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tafinlar"
    ],
    "proposition_id": 90,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tafinlar:0"
  },
  {
    "id": 932,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult patients with stage 3 melanoma with a BRAF V600 variant, following complete resection.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tafinlar"
    ],
    "proposition_id": 89,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tafinlar:1"
  },
  {
    "id": 933,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult patients with stage 3 melanoma with a BRAF V600 variant, following complete resection.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tafinlar"
    ],
    "proposition_id": 90,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tafinlar:1"
  },
  {
    "id": 934,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tafinlar"
    ],
    "proposition_id": 91,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tafinlar:2"
  },
  {
    "id": 935,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tafinlar"
    ],
    "proposition_id": 627,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tafinlar:2"
  },
  {
    "id": 936,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized osimertinib for the adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution variants.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tagrisso"
    ],
    "proposition_id": 304,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tagrisso:0"
  },
  {
    "id": 937,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized osimertinib for the adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution variants.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tagrisso"
    ],
    "proposition_id": 305,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tagrisso:0"
  },
  {
    "id": 938,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized osimertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR variants.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tagrisso"
    ],
    "proposition_id": 664,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tagrisso:1"
  },
  {
    "id": 939,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized osimertinib for treatment of adult patients with locally advanced or metastatic EGFR p.T790M mutation-positive non-small cell lung cancer.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tagrisso"
    ],
    "proposition_id": 310,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tagrisso:2"
  },
  {
    "id": 940,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tagrisso"
    ],
    "proposition_id": 665,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tagrisso:3"
  },
  {
    "id": 941,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tagrisso"
    ],
    "proposition_id": 666,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tagrisso:3"
  },
  {
    "id": 942,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tagrisso"
    ],
    "proposition_id": 667,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tagrisso:3"
  },
  {
    "id": 943,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tagrisso"
    ],
    "proposition_id": 668,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tagrisso:3"
  },
  {
    "id": 944,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.talzenna"
    ],
    "proposition_id": 412,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.talzenna:0"
  },
  {
    "id": 945,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.talzenna"
    ],
    "proposition_id": 413,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.talzenna:0"
  },
  {
    "id": 946,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized erlotinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating variants. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tarceva"
    ],
    "proposition_id": 669,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tarceva:0"
  },
  {
    "id": 947,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized erlotinib for switch maintenance treatemnt of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating variants and stable disease after first-line chemotherapy. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tarceva"
    ],
    "proposition_id": 669,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tarceva:1"
  },
  {
    "id": 948,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia (CML) in the chronic phase.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tasigna"
    ],
    "proposition_id": 670,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tasigna:0"
  },
  {
    "id": 949,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy including imatinib. Nilotinib's product information further states that efficacy data in patients with CML in blast crisis are not available.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tasigna"
    ],
    "proposition_id": 670,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tasigna:1"
  },
  {
    "id": 950,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of pediatric patients with chronic phase Phildelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tasigna"
    ],
    "proposition_id": 670,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tasigna:2"
  },
  {
    "id": 951,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are considered cisplatin ineligible, and whose tumors have PD-L1 expression >= 5%.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tecentriq"
    ],
    "proposition_id": 671,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tecentriq:0"
  },
  {
    "id": 952,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the adjuvant treatment following complete resection and platinum-based chemotherapy of adult patients with non-small cell lung cancer with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tecentriq"
    ],
    "proposition_id": 672,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tecentriq:1"
  },
  {
    "id": 953,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tecentriq"
    ],
    "proposition_id": 673,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tecentriq:2"
  },
  {
    "id": 954,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tecentriq"
    ],
    "proposition_id": 674,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tecentriq:2"
  },
  {
    "id": 955,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tecentriq"
    ],
    "proposition_id": 675,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tecentriq:3"
  },
  {
    "id": 956,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tecentriq"
    ],
    "proposition_id": 676,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tecentriq:3"
  },
  {
    "id": 957,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tecentriq"
    ],
    "proposition_id": 677,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tecentriq:3"
  },
  {
    "id": 958,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells or >= 10% tumor-infiltrating immune cells (IC) and who do not hvae EGFR mutant or ALK-positive NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tecentriq"
    ],
    "proposition_id": 672,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tecentriq:4"
  },
  {
    "id": 959,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells or >= 10% tumor-infiltrating immune cells (IC) and who do not hvae EGFR mutant or ALK-positive NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tecentriq"
    ],
    "proposition_id": 678,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tecentriq:4"
  },
  {
    "id": 960,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tecentriq"
    ],
    "proposition_id": 36,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tecentriq:5"
  },
  {
    "id": 961,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tecentriq"
    ],
    "proposition_id": 37,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tecentriq:5"
  },
  {
    "id": 962,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tecentriq"
    ],
    "proposition_id": 679,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tecentriq:6"
  },
  {
    "id": 963,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tepmetko"
    ],
    "proposition_id": 414,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tepmetko:0"
  },
  {
    "id": 964,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tepmetko"
    ],
    "proposition_id": 415,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tepmetko:0"
  },
  {
    "id": 965,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tibsovo"
    ],
    "proposition_id": 180,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tibsovo:0"
  },
  {
    "id": 966,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tibsovo"
    ],
    "proposition_id": 181,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tibsovo:0"
  },
  {
    "id": 967,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tibsovo"
    ],
    "proposition_id": 182,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tibsovo:0"
  },
  {
    "id": 968,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tibsovo"
    ],
    "proposition_id": 183,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tibsovo:0"
  },
  {
    "id": 969,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tibsovo"
    ],
    "proposition_id": 184,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tibsovo:0"
  },
  {
    "id": 970,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tibsovo"
    ],
    "proposition_id": 190,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tibsovo:1"
  },
  {
    "id": 971,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tibsovo"
    ],
    "proposition_id": 191,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tibsovo:1"
  },
  {
    "id": 972,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tibsovo"
    ],
    "proposition_id": 192,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tibsovo:1"
  },
  {
    "id": 973,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tibsovo"
    ],
    "proposition_id": 193,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tibsovo:1"
  },
  {
    "id": 974,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tibsovo"
    ],
    "proposition_id": 194,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tibsovo:1"
  },
  {
    "id": 975,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      13,
      28
    ],
    "reportedIn": [
      "doc:ema.tremelimumab-astrazeneca"
    ],
    "proposition_id": 104,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tremelimumab-astrazeneca:0",
    "status": "Withdrawn"
  },
  {
    "id": 976,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      13,
      28
    ],
    "reportedIn": [
      "doc:ema.tremelimumab-astrazeneca"
    ],
    "proposition_id": 105,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tremelimumab-astrazeneca:0",
    "status": "Withdrawn"
  },
  {
    "id": 977,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      13,
      28
    ],
    "reportedIn": [
      "doc:ema.tremelimumab-astrazeneca"
    ],
    "proposition_id": 107,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tremelimumab-astrazeneca:0",
    "status": "Withdrawn"
  },
  {
    "id": 978,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      13,
      28
    ],
    "reportedIn": [
      "doc:ema.tremelimumab-astrazeneca"
    ],
    "proposition_id": 106,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tremelimumab-astrazeneca:0",
    "status": "Withdrawn"
  },
  {
    "id": 979,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "contributions": [
      13,
      28
    ],
    "reportedIn": [
      "doc:ema.tremelimumab-astrazeneca"
    ],
    "proposition_id": 108,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tremelimumab-astrazeneca:0",
    "status": "Withdrawn"
  },
  {
    "id": 980,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized arsenic trioxide for induction of remission, and consolidation in adult patients with either newly diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) (white blood cell count, <= 10 x 10^3 / ul) in combination with all-trans-retinoic acid (ATRA) or relapsed / refractory acute promyelocytic leukemia (APL) (previous treatment should have included a retinoid and chemotherapy). Both contexts should be characterized by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukemia / retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.trisenox"
    ],
    "proposition_id": 28,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.trisenox:0"
  },
  {
    "id": 981,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.trodelvy"
    ],
    "proposition_id": 403,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.trodelvy:0"
  },
  {
    "id": 982,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.trodelvy"
    ],
    "proposition_id": 404,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.trodelvy:1"
  },
  {
    "id": 983,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.trodelvy"
    ],
    "proposition_id": 405,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.trodelvy:1"
  },
  {
    "id": 984,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.trodelvy"
    ],
    "proposition_id": 406,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.trodelvy:1"
  },
  {
    "id": 985,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have at least 2 prior anti-HER2 treatment regimens.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tukysa"
    ],
    "proposition_id": 425,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tukysa:0"
  },
  {
    "id": 986,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with capecitabine for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tyverb"
    ],
    "proposition_id": 195,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tyverb:0"
  },
  {
    "id": 987,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with trastuzumab for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tyverb"
    ],
    "proposition_id": 685,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tyverb:1"
  },
  {
    "id": 988,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. This indication states that the patients in the registration study were not previosuly treated with trastuzumab or an aromatase inhibitor and that no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. This indication is based on the randomized, double-blind, and placebo controlled phase 3 study EGF30008, which used Letrozole as an aromatase inhibitor. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tyverb"
    ],
    "proposition_id": 198,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tyverb:2"
  },
  {
    "id": 989,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with capecitabine for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tyverb"
    ],
    "proposition_id": 687,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tyverb:0"
  },
  {
    "id": 990,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with trastuzumab for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tyverb"
    ],
    "proposition_id": 688,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tyverb:1"
  },
  {
    "id": 991,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. This indication states that the patients in the registration study were not previosuly treated with trastuzumab or an aromatase inhibitor and that no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. This indication is based on the randomized, double-blind, and placebo controlled phase 3 study EGF30008, which used Letrozole as an aromatase inhibitor. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tyverb"
    ],
    "proposition_id": 689,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tyverb:2"
  },
  {
    "id": 992,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.vectibix"
    ],
    "proposition_id": 690,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.vectibix:0"
  },
  {
    "id": 993,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.vectibix"
    ],
    "proposition_id": 691,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.vectibix:0"
  },
  {
    "id": 994,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFIRI for the second-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.vectibix"
    ],
    "proposition_id": 691,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.vectibix:1"
  },
  {
    "id": 995,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized panitumumab as a monotherapy for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.vectibix"
    ],
    "proposition_id": 692,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.vectibix:2"
  },
  {
    "id": 996,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.venclyxto"
    ],
    "proposition_id": 693,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.venclyxto:0"
  },
  {
    "id": 997,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.venclyxto"
    ],
    "proposition_id": 694,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.venclyxto:0"
  },
  {
    "id": 998,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.venclyxto"
    ],
    "proposition_id": 695,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.venclyxto:0"
  },
  {
    "id": 999,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.venclyxto"
    ],
    "proposition_id": 696,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.venclyxto:1"
  },
  {
    "id": 1000,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.venclyxto"
    ],
    "proposition_id": 695,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.venclyxto:1"
  },
  {
    "id": 1001,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 3,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:1"
  },
  {
    "id": 1002,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 4,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:1"
  },
  {
    "id": 1003,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 5,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:1"
  },
  {
    "id": 1004,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 6,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:1"
  },
  {
    "id": 1005,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 7,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:1"
  },
  {
    "id": 1006,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 8,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:1"
  },
  {
    "id": 1007,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 9,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:1"
  },
  {
    "id": 1008,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 10,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:1"
  },
  {
    "id": 1009,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 11,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:1"
  },
  {
    "id": 1010,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.vitrakvi"
    ],
    "proposition_id": 199,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.vitrakvi:0"
  },
  {
    "id": 1011,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.vitrakvi"
    ],
    "proposition_id": 200,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.vitrakvi:0"
  },
  {
    "id": 1012,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.vitrakvi"
    ],
    "proposition_id": 201,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.vitrakvi:0"
  },
  {
    "id": 1013,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized dacomitinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating variants.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.vizimpro"
    ],
    "proposition_id": 708,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.vizimpro:0"
  },
  {
    "id": 1014,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized crizotinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.xalkori"
    ],
    "proposition_id": 84,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.xalkori:0"
  },
  {
    "id": 1015,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.xalkori"
    ],
    "proposition_id": 84,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.xalkori:1"
  },
  {
    "id": 1016,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.xalkori"
    ],
    "proposition_id": 85,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.xalkori:2"
  },
  {
    "id": 1017,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.xalkori"
    ],
    "proposition_id": 86,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.xalkori:3"
  },
  {
    "id": 1018,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumor (IMT).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.xalkori"
    ],
    "proposition_id": 87,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.xalkori:4"
  },
  {
    "id": 1019,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib's product information states that, before taking gilteritinib, relapsed or refactory AML patients must have confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test. The product information describes the mechanism of action for gilteritinib as inhibiting FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and that it induces apoptosis in leukemic cells expressing FLT3-ITD.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.xospata"
    ],
    "proposition_id": 709,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.xospata:0"
  },
  {
    "id": 1020,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib's product information states that, before taking gilteritinib, relapsed or refactory AML patients must have confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test. The product information describes the mechanism of action for gilteritinib as inhibiting FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and that it induces apoptosis in leukemic cells expressing FLT3-ITD.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.xospata"
    ],
    "proposition_id": 710,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.xospata:0"
  },
  {
    "id": 1021,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.yervoy"
    ],
    "proposition_id": 172,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.yervoy:0"
  },
  {
    "id": 1022,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.yervoy"
    ],
    "proposition_id": 173,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.yervoy:0"
  },
  {
    "id": 1023,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.yervoy"
    ],
    "proposition_id": 174,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.yervoy:0"
  },
  {
    "id": 1024,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.yervoy"
    ],
    "proposition_id": 169,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.yervoy:1"
  },
  {
    "id": 1025,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.yervoy"
    ],
    "proposition_id": 507,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.yervoy:1"
  },
  {
    "id": 1026,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.yervoy"
    ],
    "proposition_id": 642,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.yervoy:2"
  },
  {
    "id": 1027,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Vemurafenib's product information states the special warning and caution that the efficacy and safety of vemurafenib in patients with tumors expressing rare BRAF V600 mutations other than V600E and V600K have not been convincingly established.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.zelboraf"
    ],
    "proposition_id": 426,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.zelboraf:0"
  },
  {
    "id": 1028,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Vemurafenib's product information states the special warning and caution that the efficacy and safety of vemurafenib in patients with tumors expressing rare BRAF V600 mutations other than V600E and V600K have not been convincingly established.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.zelboraf"
    ],
    "proposition_id": 711,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.zelboraf:0"
  },
  {
    "id": 1029,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.zydelig"
    ],
    "proposition_id": 712,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.zydelig:0"
  },
  {
    "id": 1030,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.zydelig"
    ],
    "proposition_id": 713,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.zydelig:0"
  },
  {
    "id": 1031,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.zydelig"
    ],
    "proposition_id": 714,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.zydelig:0"
  },
  {
    "id": 1032,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ceritinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.zykadia"
    ],
    "proposition_id": 77,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.zykadia:0"
  },
  {
    "id": 1033,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized ceritinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.zykadia"
    ],
    "proposition_id": 77,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.zykadia:1"
  },
  {
    "id": 1034,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized tislelizumab in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% of tumor cells with no EGFR or ALK positive mutations and who have either (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC. This indication is based on BGB-A317-304, a randomized, open-label, and multicenter phase 3 study where patients were randomized (2:1) to receive tislelizumab in combination with pemetrexed and carboplatin or cisplatin (n=223) or pemetrexed and carboplatin or cisplatin (n=111), where the choice of platinum (cisplatin or carboplatin) was the investigator's choice. Tislelizumab's product information further states that the study excluded patients with active brain or leptomeningeal metastases, known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids or other immunosuppressants.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tevimbra"
    ],
    "proposition_id": 715,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tevimbra:0"
  },
  {
    "id": 1035,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized tislelizumab in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% of tumor cells with no EGFR or ALK positive mutations and who have either (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC. This indication is based on BGB-A317-304, a randomized, open-label, and multicenter phase 3 study where patients were randomized (2:1) to receive tislelizumab in combination with pemetrexed and carboplatin or cisplatin (n=223) or pemetrexed and carboplatin or cisplatin (n=111), where the choice of platinum (cisplatin or carboplatin) was the investigator's choice. Tislelizumab's product information further states that the study excluded patients with active brain or leptomeningeal metastases, known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids or other immunosuppressants.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.tevimbra"
    ],
    "proposition_id": 716,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tevimbra:0"
  },
  {
    "id": 1036,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.rybrevant"
    ],
    "proposition_id": 26,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rybrevant:0"
  },
  {
    "id": 1037,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized amivantamab as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations, after failure of platinum-based chemotherapy.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.rybrevant"
    ],
    "proposition_id": 27,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rybrevant:1"
  },
  {
    "id": 1038,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.truqap"
    ],
    "proposition_id": 717,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.truqap:0"
  },
  {
    "id": 1039,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.truqap"
    ],
    "proposition_id": 718,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.truqap:0"
  },
  {
    "id": 1040,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.truqap"
    ],
    "proposition_id": 58,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.truqap:0"
  },
  {
    "id": 1041,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.truqap"
    ],
    "proposition_id": 55,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.truqap:0"
  },
  {
    "id": 1042,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.truqap"
    ],
    "proposition_id": 61,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.truqap:0"
  },
  {
    "id": 1043,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.truqap"
    ],
    "proposition_id": 64,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.truqap:0"
  },
  {
    "id": 1044,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.truqap"
    ],
    "proposition_id": 67,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.truqap:0"
  },
  {
    "id": 1045,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.truqap"
    ],
    "proposition_id": 70,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.truqap:0"
  },
  {
    "id": 1046,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.balversa"
    ],
    "proposition_id": 719,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.balversa:0"
  },
  {
    "id": 1047,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.balversa"
    ],
    "proposition_id": 720,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.balversa:0"
  },
  {
    "id": 1048,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.balversa"
    ],
    "proposition_id": 128,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.balversa:0"
  },
  {
    "id": 1049,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.balversa"
    ],
    "proposition_id": 721,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.balversa:0"
  },
  {
    "id": 1050,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.balversa"
    ],
    "proposition_id": 124,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.balversa:0"
  },
  {
    "id": 1051,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.balversa"
    ],
    "proposition_id": 125,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.balversa:0"
  },
  {
    "id": 1052,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.balversa"
    ],
    "proposition_id": 126,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.balversa:0"
  },
  {
    "id": 1053,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.balversa"
    ],
    "proposition_id": 127,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.balversa:0"
  },
  {
    "id": 1054,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocracinoma whose tumors are Claudin (CLDN) 18.2 positive. The product information states that eligible patients should have CLDN18.2 positive tumor defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining, assessed by a CE-marked IVD with the corresponding intended purpose. The product information further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.vyloy"
    ],
    "proposition_id": 513,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.vyloy:0"
  },
  {
    "id": 1055,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocracinoma whose tumors are Claudin (CLDN) 18.2 positive. The product information states that eligible patients should have CLDN18.2 positive tumor defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining, assessed by a CE-marked IVD with the corresponding intended purpose. The product information further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.vyloy"
    ],
    "proposition_id": 514,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.vyloy:0"
  },
  {
    "id": 1056,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 0,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:0"
  },
  {
    "id": 1057,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 1,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:0"
  },
  {
    "id": 1058,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 2,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:0"
  },
  {
    "id": 1059,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 3,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:0"
  },
  {
    "id": 1060,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 4,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:0"
  },
  {
    "id": 1061,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 5,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:0"
  },
  {
    "id": 1062,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 6,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:0"
  },
  {
    "id": 1063,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 7,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:0"
  },
  {
    "id": 1064,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 8,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:0"
  },
  {
    "id": 1065,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 792,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:0"
  },
  {
    "id": 1066,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 793,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:0"
  },
  {
    "id": 1067,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.verzenios"
    ],
    "proposition_id": 794,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.verzenios:0"
  },
  {
    "id": 1068,
    "type": "Statement",
    "description": "",
    "contributions": [
      15
    ],
    "reportedIn": [
      "doc:ema.blincyto"
    ],
    "proposition_id": 46,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.blincyto:4"
  },
  {
    "id": 1069,
    "type": "Statement",
    "description": "",
    "contributions": [
      16
    ],
    "reportedIn": [
      "doc:ema.bosulif"
    ],
    "proposition_id": 47,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.bosulif:2"
  },
  {
    "id": 1070,
    "type": "Statement",
    "description": "",
    "contributions": [
      16
    ],
    "reportedIn": [
      "doc:ema.bosulif"
    ],
    "proposition_id": 545,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.bosulif:0"
  },
  {
    "id": 1071,
    "type": "Statement",
    "description": "",
    "contributions": [
      16
    ],
    "reportedIn": [
      "doc:ema.bosulif"
    ],
    "proposition_id": 545,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.bosulif:1"
  },
  {
    "id": 1072,
    "type": "Statement",
    "description": "",
    "contributions": [
      16
    ],
    "reportedIn": [
      "doc:ema.bosulif"
    ],
    "proposition_id": 545,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.bosulif:2"
  },
  {
    "id": 1073,
    "type": "Statement",
    "description": "",
    "contributions": [
      17
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 859,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:4"
  },
  {
    "id": 1074,
    "type": "Statement",
    "description": "",
    "contributions": [
      17
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 860,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:4"
  },
  {
    "id": 1075,
    "type": "Statement",
    "description": "",
    "contributions": [
      17
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 861,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:4"
  },
  {
    "id": 1076,
    "type": "Statement",
    "description": "",
    "contributions": [
      17
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 862,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:4"
  },
  {
    "id": 1077,
    "type": "Statement",
    "description": "",
    "contributions": [
      17
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 863,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:4"
  },
  {
    "id": 1078,
    "type": "Statement",
    "description": "",
    "contributions": [
      17
    ],
    "reportedIn": [
      "doc:ema.enhertu"
    ],
    "proposition_id": 864,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.enhertu:4"
  },
  {
    "id": 1079,
    "type": "Statement",
    "description": "",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 159,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:0"
  },
  {
    "id": 1080,
    "type": "Statement",
    "description": "",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.glivec"
    ],
    "proposition_id": 159,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.glivec:1"
  },
  {
    "id": 1081,
    "type": "Statement",
    "description": "",
    "contributions": [
      19
    ],
    "reportedIn": [
      "doc:ema.imfinzi"
    ],
    "proposition_id": 474,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.imfinzi:3"
  },
  {
    "id": 1082,
    "type": "Statement",
    "description": "",
    "contributions": [
      19
    ],
    "reportedIn": [
      "doc:ema.imfinzi"
    ],
    "proposition_id": 475,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.imfinzi:3"
  },
  {
    "id": 1083,
    "type": "Statement",
    "description": "",
    "contributions": [
      19
    ],
    "reportedIn": [
      "doc:ema.imfinzi"
    ],
    "proposition_id": 476,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.imfinzi:3"
  },
  {
    "id": 1084,
    "type": "Statement",
    "description": "",
    "contributions": [
      19
    ],
    "reportedIn": [
      "doc:ema.imfinzi"
    ],
    "proposition_id": 477,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.imfinzi:3"
  },
  {
    "id": 1085,
    "type": "Statement",
    "description": "",
    "contributions": [
      21
    ],
    "reportedIn": [
      "doc:ema.kisqali"
    ],
    "proposition_id": 499,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kisqali:1"
  },
  {
    "id": 1086,
    "type": "Statement",
    "description": "",
    "contributions": [
      21
    ],
    "reportedIn": [
      "doc:ema.kisqali"
    ],
    "proposition_id": 500,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kisqali:1"
  },
  {
    "id": 1087,
    "type": "Statement",
    "description": "",
    "contributions": [
      21
    ],
    "reportedIn": [
      "doc:ema.kisqali"
    ],
    "proposition_id": 501,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kisqali:1"
  },
  {
    "id": 1088,
    "type": "Statement",
    "description": "",
    "contributions": [
      21
    ],
    "reportedIn": [
      "doc:ema.kisqali"
    ],
    "proposition_id": 502,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kisqali:1"
  },
  {
    "id": 1089,
    "type": "Statement",
    "description": "",
    "contributions": [
      21
    ],
    "reportedIn": [
      "doc:ema.kisqali"
    ],
    "proposition_id": 503,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kisqali:1"
  },
  {
    "id": 1090,
    "type": "Statement",
    "description": "",
    "contributions": [
      21
    ],
    "reportedIn": [
      "doc:ema.kisqali"
    ],
    "proposition_id": 504,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.kisqali:1"
  },
  {
    "id": 1091,
    "type": "Statement",
    "description": "",
    "contributions": [
      22
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 169,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:7"
  },
  {
    "id": 1092,
    "type": "Statement",
    "description": "",
    "contributions": [
      22
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 507,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:7"
  },
  {
    "id": 1093,
    "type": "Statement",
    "description": "",
    "contributions": [
      23
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 638,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:8"
  },
  {
    "id": 1094,
    "type": "Statement",
    "description": "",
    "contributions": [
      23
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 768,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:8"
  },
  {
    "id": 1095,
    "type": "Statement",
    "description": "",
    "contributions": [],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 639,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:8"
  },
  {
    "id": 1096,
    "type": "Statement",
    "description": "",
    "contributions": [
      23
    ],
    "reportedIn": [
      "doc:ema.opdivo"
    ],
    "proposition_id": 865,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.opdivo:8"
  },
  {
    "id": 1097,
    "type": "Statement",
    "description": "",
    "contributions": [
      24
    ],
    "reportedIn": [
      "doc:ema.rybrevant"
    ],
    "proposition_id": 465,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rybrevant:2"
  },
  {
    "id": 1098,
    "type": "Statement",
    "description": "",
    "contributions": [
      24
    ],
    "reportedIn": [
      "doc:ema.rybrevant"
    ],
    "proposition_id": 466,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rybrevant:2"
  },
  {
    "id": 1099,
    "type": "Statement",
    "description": "",
    "contributions": [
      24
    ],
    "reportedIn": [
      "doc:ema.rybrevant"
    ],
    "proposition_id": 464,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rybrevant:2"
  },
  {
    "id": 1100,
    "type": "Statement",
    "description": "",
    "contributions": [
      24
    ],
    "reportedIn": [
      "doc:ema.rybrevant"
    ],
    "proposition_id": 463,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rybrevant:2"
  },
  {
    "id": 1101,
    "type": "Statement",
    "description": "",
    "contributions": [
      25
    ],
    "reportedIn": [
      "doc:ema.tagrisso"
    ],
    "proposition_id": 304,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tagrisso:4"
  },
  {
    "id": 1102,
    "type": "Statement",
    "description": "",
    "contributions": [
      25
    ],
    "reportedIn": [
      "doc:ema.tagrisso"
    ],
    "proposition_id": 305,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tagrisso:4"
  },
  {
    "id": 1103,
    "type": "Statement",
    "description": "",
    "contributions": [
      26
    ],
    "reportedIn": [
      "doc:ema.tevimbra"
    ],
    "proposition_id": 866,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tevimbra:1"
  },
  {
    "id": 1104,
    "type": "Statement",
    "description": "",
    "contributions": [
      26
    ],
    "reportedIn": [
      "doc:ema.tevimbra"
    ],
    "proposition_id": 867,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tevimbra:1"
  },
  {
    "id": 1105,
    "type": "Statement",
    "description": "",
    "contributions": [
      26
    ],
    "reportedIn": [
      "doc:ema.tevimbra"
    ],
    "proposition_id": 868,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tevimbra:1"
  },
  {
    "id": 1106,
    "type": "Statement",
    "description": "",
    "contributions": [
      26
    ],
    "reportedIn": [
      "doc:ema.tevimbra"
    ],
    "proposition_id": 869,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tevimbra:1"
  },
  {
    "id": 1107,
    "type": "Statement",
    "description": "",
    "contributions": [
      26
    ],
    "reportedIn": [
      "doc:ema.tevimbra"
    ],
    "proposition_id": 870,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tevimbra:1"
  },
  {
    "id": 1108,
    "type": "Statement",
    "description": "",
    "contributions": [
      26
    ],
    "reportedIn": [
      "doc:ema.tevimbra"
    ],
    "proposition_id": 871,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tevimbra:1"
  },
  {
    "id": 1109,
    "type": "Statement",
    "description": "",
    "contributions": [
      26
    ],
    "reportedIn": [
      "doc:ema.tevimbra"
    ],
    "proposition_id": 872,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tevimbra:2"
  },
  {
    "id": 1110,
    "type": "Statement",
    "description": "",
    "contributions": [
      26
    ],
    "reportedIn": [
      "doc:ema.tevimbra"
    ],
    "proposition_id": 873,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.tevimbra:2"
  },
  {
    "id": 1111,
    "type": "Statement",
    "description": "",
    "contributions": [
      29
    ],
    "reportedIn": [
      "doc:ema.yervoy"
    ],
    "proposition_id": 169,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.yervoy:3"
  },
  {
    "id": 1112,
    "type": "Statement",
    "description": "",
    "contributions": [
      29
    ],
    "reportedIn": [
      "doc:ema.yervoy"
    ],
    "proposition_id": 507,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.yervoy:3"
  },
  {
    "id": 1113,
    "type": "Statement",
    "description": "",
    "contributions": [
      30
    ],
    "reportedIn": [
      "doc:ema.augtyro"
    ],
    "proposition_id": 368,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.augtyro:0"
  },
  {
    "id": 1114,
    "type": "Statement",
    "description": "",
    "contributions": [
      30
    ],
    "reportedIn": [
      "doc:ema.augtyro"
    ],
    "proposition_id": 369,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.augtyro:1"
  },
  {
    "id": 1115,
    "type": "Statement",
    "description": "",
    "contributions": [
      30
    ],
    "reportedIn": [
      "doc:ema.augtyro"
    ],
    "proposition_id": 370,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.augtyro:1"
  },
  {
    "id": 1116,
    "type": "Statement",
    "description": "",
    "contributions": [
      30
    ],
    "reportedIn": [
      "doc:ema.augtyro"
    ],
    "proposition_id": 371,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.augtyro:1"
  },
  {
    "id": 1117,
    "type": "Statement",
    "description": "",
    "contributions": [
      31
    ],
    "reportedIn": [
      "doc:ema.lazcluze"
    ],
    "proposition_id": 463,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lazcluze:0"
  },
  {
    "id": 1118,
    "type": "Statement",
    "description": "",
    "contributions": [
      31
    ],
    "reportedIn": [
      "doc:ema.lazcluze"
    ],
    "proposition_id": 464,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.lazcluze:0"
  },
  {
    "id": 1119,
    "type": "Statement",
    "description": "",
    "contributions": [
      32
    ],
    "reportedIn": [
      "doc:ema.elahere"
    ],
    "proposition_id": 467,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.elahere:0"
  },
  {
    "id": 1120,
    "type": "Statement",
    "description": "",
    "contributions": [
      32
    ],
    "reportedIn": [
      "doc:ema.elahere"
    ],
    "proposition_id": 468,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.elahere:0"
  },
  {
    "id": 1121,
    "type": "Statement",
    "description": "",
    "contributions": [
      32
    ],
    "reportedIn": [
      "doc:ema.elahere"
    ],
    "proposition_id": 469,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.elahere:0"
  },
  {
    "id": 1122,
    "type": "Statement",
    "description": "",
    "contributions": [
      33
    ],
    "reportedIn": [
      "doc:ema.itovebi"
    ],
    "proposition_id": 510,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.itovebi:0"
  },
  {
    "id": 1123,
    "type": "Statement",
    "description": "",
    "contributions": [
      33
    ],
    "reportedIn": [
      "doc:ema.itovebi"
    ],
    "proposition_id": 511,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.itovebi:0"
  },
  {
    "id": 1124,
    "type": "Statement",
    "description": "",
    "contributions": [
      33
    ],
    "reportedIn": [
      "doc:ema.itovebi"
    ],
    "proposition_id": 512,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.itovebi:0"
  },
  {
    "id": 1125,
    "type": "Statement",
    "description": "",
    "contributions": [
      34
    ],
    "reportedIn": [
      "doc:ema.ziihera"
    ],
    "proposition_id": 515,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.ziihera:0"
  },
  {
    "id": 1126,
    "type": "Statement",
    "description": "",
    "contributions": [
      34
    ],
    "reportedIn": [
      "doc:ema.ziihera"
    ],
    "proposition_id": 516,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.ziihera:0"
  },
  {
    "id": 1127,
    "type": "Statement",
    "description": "",
    "contributions": [
      34
    ],
    "reportedIn": [
      "doc:ema.ziihera"
    ],
    "proposition_id": 517,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.ziihera:0"
  },
  {
    "id": 1128,
    "type": "Statement",
    "description": "",
    "contributions": [
      35
    ],
    "reportedIn": [
      "doc:fda.modeyso"
    ],
    "proposition_id": 874,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.modeyso:0"
  },
  {
    "id": 1129,
    "type": "Statement",
    "description": "",
    "contributions": [
      36
    ],
    "reportedIn": [
      "doc:fda.inluriyo"
    ],
    "proposition_id": 875,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.inluriyo:0"
  },
  {
    "id": 1130,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 479,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1131,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 480,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1132,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 481,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1133,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 482,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1134,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 483,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1135,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 484,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1136,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 485,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1137,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 486,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1138,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 487,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1139,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 488,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1140,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 489,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1141,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 490,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1142,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 491,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1143,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 492,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1144,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 493,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1145,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 494,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1146,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 495,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1147,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 496,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1148,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 497,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1149,
    "type": "Statement",
    "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "contributions": [
      37
    ],
    "reportedIn": [
      "doc:ema.voranigo"
    ],
    "proposition_id": 498,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.voranigo:0"
  },
  {
    "id": 1150,
    "type": "Statement",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. The label notes that this indication is approved under accelerated approval based on tumor response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This indication is based on MOUNTAINEER (NCT03043313), an open-label, multicenter trial where RAS status was performed as standard of care prior to study entry based on expanded RAS testing including KRAS exons 2, 3, and 4 and NRAS exons 2, 3, and 4.",
    "contributions": [
      38
    ],
    "reportedIn": [
      "doc:fda.tukysa"
    ],
    "proposition_id": 876,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.tukysa:1"
  },
  {
    "id": 1151,
    "type": "Statement",
    "description": "",
    "contributions": [
      39
    ],
    "reportedIn": [
      "doc:fda.vanflyta"
    ],
    "proposition_id": 877,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.vanflyta:0"
  },
  {
    "id": 1152,
    "type": "Statement",
    "description": "",
    "contributions": [
      39
    ],
    "reportedIn": [
      "doc:fda.vanflyta"
    ],
    "proposition_id": 878,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.vanflyta:0"
  },
  {
    "id": 1153,
    "type": "Statement",
    "description": "",
    "contributions": [
      39
    ],
    "reportedIn": [
      "doc:fda.vanflyta"
    ],
    "proposition_id": 879,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.vanflyta:0"
  },
  {
    "id": 1154,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mekinist"
    ],
    "proposition_id": 89,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mekinist:2"
  },
  {
    "id": 1155,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:fda.mekinist"
    ],
    "proposition_id": 90,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.mekinist:2"
  },
  {
    "id": 1156,
    "type": "Statement",
    "description": "",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.rybrevant"
    ],
    "proposition_id": 463,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rybrevant:3"
  },
  {
    "id": 1157,
    "type": "Statement",
    "description": "",
    "contributions": [
      13
    ],
    "reportedIn": [
      "doc:ema.rybrevant"
    ],
    "proposition_id": 464,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:ema.rybrevant:3"
  },
  {
    "id": 1158,
    "type": "Statement",
    "description": "",
    "contributions": [
      40
    ],
    "reportedIn": [
      "doc:fda.imbruvica"
    ],
    "proposition_id": 749,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:fda.imbruvica:0"
  },
  {
    "id": 1159,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00221"
    ],
    "proposition_id": 560,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00221:a"
  },
  {
    "id": 1160,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00401"
    ],
    "proposition_id": 22,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00401:a"
  },
  {
    "id": 1161,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00401"
    ],
    "proposition_id": 22,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00401:b"
  },
  {
    "id": 1162,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00847"
    ],
    "proposition_id": 659,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00847:a"
  },
  {
    "id": 1163,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00224"
    ],
    "proposition_id": 47,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00224:a"
  },
  {
    "id": 1164,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00562"
    ],
    "proposition_id": 50,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00562:a"
  },
  {
    "id": 1165,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00562"
    ],
    "proposition_id": 50,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00562:b"
  },
  {
    "id": 1166,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00340"
    ],
    "proposition_id": 77,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00340:a"
  },
  {
    "id": 1167,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00373"
    ],
    "proposition_id": 82,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00373:a"
  },
  {
    "id": 1168,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00373"
    ],
    "proposition_id": 83,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00373:a"
  },
  {
    "id": 1169,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00243"
    ],
    "proposition_id": 84,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00243:a"
  },
  {
    "id": 1170,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00237"
    ],
    "proposition_id": 88,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00237:a"
  },
  {
    "id": 1171,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00237"
    ],
    "proposition_id": 663,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00237:a"
  },
  {
    "id": 1172,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00565"
    ],
    "proposition_id": 708,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00565:a"
  },
  {
    "id": 1173,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00563"
    ],
    "proposition_id": 41,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00563:a"
  },
  {
    "id": 1174,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00563"
    ],
    "proposition_id": 42,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00563:a"
  },
  {
    "id": 1175,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00702"
    ],
    "proposition_id": 120,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00702:a"
  },
  {
    "id": 1176,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00570"
    ],
    "proposition_id": 203,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00570:a"
  },
  {
    "id": 1177,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00570"
    ],
    "proposition_id": 203,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00570:b"
  },
  {
    "id": 1178,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00682"
    ],
    "proposition_id": 208,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00682:a"
  },
  {
    "id": 1179,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00720"
    ],
    "proposition_id": 629,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00720:a"
  },
  {
    "id": 1180,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00720"
    ],
    "proposition_id": 630,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00720:a"
  },
  {
    "id": 1181,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00720"
    ],
    "proposition_id": 631,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00720:a"
  },
  {
    "id": 1182,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00720"
    ],
    "proposition_id": 632,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00720:a"
  },
  {
    "id": 1183,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00720"
    ],
    "proposition_id": 633,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00720:a"
  },
  {
    "id": 1184,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00720"
    ],
    "proposition_id": 634,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00720:a"
  },
  {
    "id": 1185,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00848"
    ],
    "proposition_id": 537,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00848:a"
  },
  {
    "id": 1186,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00848"
    ],
    "proposition_id": 538,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00848:a"
  },
  {
    "id": 1187,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00848"
    ],
    "proposition_id": 539,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00848:a"
  },
  {
    "id": 1188,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 243,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1189,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 245,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1190,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 244,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1191,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 246,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1192,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 248,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1193,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 250,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1194,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 249,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1195,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 251,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1196,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 253,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1197,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 256,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1198,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 254,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1199,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 247,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1200,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 252,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1201,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00746"
    ],
    "proposition_id": 257,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00746:abc"
  },
  {
    "id": 1202,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 231,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:abc"
  },
  {
    "id": 1203,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 233,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:abc"
  },
  {
    "id": 1204,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 232,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:abc"
  },
  {
    "id": 1205,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 234,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:abc"
  },
  {
    "id": 1206,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 235,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:abc"
  },
  {
    "id": 1207,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 237,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:abc"
  },
  {
    "id": 1208,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 236,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:abc"
  },
  {
    "id": 1209,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 238,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:abc"
  },
  {
    "id": 1210,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 239,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:abc"
  },
  {
    "id": 1211,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 241,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:abc"
  },
  {
    "id": 1212,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 240,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:abc"
  },
  {
    "id": 1213,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 242,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:abc"
  },
  {
    "id": 1214,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 231,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:def"
  },
  {
    "id": 1215,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 233,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:def"
  },
  {
    "id": 1216,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 232,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:def"
  },
  {
    "id": 1217,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 234,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:def"
  },
  {
    "id": 1218,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 235,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:def"
  },
  {
    "id": 1219,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 237,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:def"
  },
  {
    "id": 1220,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 236,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:def"
  },
  {
    "id": 1221,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 238,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:def"
  },
  {
    "id": 1222,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 239,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:def"
  },
  {
    "id": 1223,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 241,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:def"
  },
  {
    "id": 1224,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 240,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:def"
  },
  {
    "id": 1225,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 242,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:def"
  },
  {
    "id": 1226,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 263,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:g"
  },
  {
    "id": 1227,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 265,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:g"
  },
  {
    "id": 1228,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 264,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:g"
  },
  {
    "id": 1229,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00588"
    ],
    "proposition_id": 266,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00588:g"
  },
  {
    "id": 1230,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00353"
    ],
    "proposition_id": 310,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00353:a"
  },
  {
    "id": 1231,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00353"
    ],
    "proposition_id": 664,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00353:b"
  },
  {
    "id": 1232,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00353"
    ],
    "proposition_id": 304,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00353:c"
  },
  {
    "id": 1233,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00353"
    ],
    "proposition_id": 305,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00353:c"
  },
  {
    "id": 1234,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00302"
    ],
    "proposition_id": 363,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00302:a"
  },
  {
    "id": 1235,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00302"
    ],
    "proposition_id": 582,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00302:b"
  },
  {
    "id": 1236,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00302"
    ],
    "proposition_id": 583,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00302:b"
  },
  {
    "id": 1237,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00605"
    ],
    "proposition_id": 412,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00605:a"
  },
  {
    "id": 1238,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00605"
    ],
    "proposition_id": 413,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00605:a"
  },
  {
    "id": 1239,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00415"
    ],
    "proposition_id": 89,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00415:a"
  },
  {
    "id": 1240,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00415"
    ],
    "proposition_id": 89,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00415:b"
  },
  {
    "id": 1241,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00415"
    ],
    "proposition_id": 90,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00415:a"
  },
  {
    "id": 1242,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00415"
    ],
    "proposition_id": 90,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00415:b"
  },
  {
    "id": 1243,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00102"
    ],
    "proposition_id": 426,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00102:a"
  },
  {
    "id": 1244,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00102"
    ],
    "proposition_id": 711,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00102:a"
  },
  {
    "id": 1245,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00400"
    ],
    "proposition_id": 693,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00400:a"
  },
  {
    "id": 1246,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00400"
    ],
    "proposition_id": 694,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00400:a"
  },
  {
    "id": 1247,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00400"
    ],
    "proposition_id": 695,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00400:a"
  },
  {
    "id": 1248,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00400"
    ],
    "proposition_id": 696,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00400:b"
  },
  {
    "id": 1249,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00708"
    ],
    "proposition_id": 741,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00708:b"
  },
  {
    "id": 1250,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00708"
    ],
    "proposition_id": 742,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00708:b"
  },
  {
    "id": 1251,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00708"
    ],
    "proposition_id": 743,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00708:b"
  },
  {
    "id": 1252,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00840"
    ],
    "proposition_id": 744,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00840:b"
  },
  {
    "id": 1253,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00840"
    ],
    "proposition_id": 745,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00840:b"
  },
  {
    "id": 1254,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00840"
    ],
    "proposition_id": 746,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00840:b"
  },
  {
    "id": 1255,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00296"
    ],
    "proposition_id": 747,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00296:b"
  },
  {
    "id": 1256,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00296"
    ],
    "proposition_id": 748,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00296:b"
  },
  {
    "id": 1257,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00296"
    ],
    "proposition_id": 749,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00296:b"
  },
  {
    "id": 1258,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00551"
    ],
    "proposition_id": 169,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00551:c"
  },
  {
    "id": 1259,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00551"
    ],
    "proposition_id": 507,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00551:c"
  },
  {
    "id": 1260,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00455"
    ],
    "proposition_id": 588,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00455:a"
  },
  {
    "id": 1261,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00455"
    ],
    "proposition_id": 589,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00455:a"
  },
  {
    "id": 1262,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00455"
    ],
    "proposition_id": 595,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00455:f"
  },
  {
    "id": 1263,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00455"
    ],
    "proposition_id": 320,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00455:h"
  },
  {
    "id": 1264,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00455"
    ],
    "proposition_id": 339,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00455:j"
  },
  {
    "id": 1265,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00455"
    ],
    "proposition_id": 324,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00455:k"
  },
  {
    "id": 1266,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00455"
    ],
    "proposition_id": 323,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00455:k"
  },
  {
    "id": 1267,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.P00760"
    ],
    "proposition_id": 199,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.P00760:a"
  },
  {
    "id": 1268,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.P00760"
    ],
    "proposition_id": 200,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.P00760:a"
  },
  {
    "id": 1269,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.P00760"
    ],
    "proposition_id": 201,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.P00760:a"
  },
  {
    "id": 1270,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00758"
    ],
    "proposition_id": 199,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00758:a"
  },
  {
    "id": 1271,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00758"
    ],
    "proposition_id": 200,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00758:a"
  },
  {
    "id": 1272,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00758"
    ],
    "proposition_id": 201,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00758:a"
  },
  {
    "id": 1273,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00219"
    ],
    "proposition_id": 669,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00219:a"
  },
  {
    "id": 1274,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00219"
    ],
    "proposition_id": 669,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00219:b"
  },
  {
    "id": 1275,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00206"
    ],
    "proposition_id": 20,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00206:a"
  },
  {
    "id": 1276,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00414"
    ],
    "proposition_id": 311,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00414:a"
  },
  {
    "id": 1277,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00414"
    ],
    "proposition_id": 312,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00414:a"
  },
  {
    "id": 1278,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00414"
    ],
    "proposition_id": 313,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00414:a"
  },
  {
    "id": 1279,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00414"
    ],
    "proposition_id": 143,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00414:b"
  },
  {
    "id": 1280,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00414"
    ],
    "proposition_id": 144,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00414:b"
  },
  {
    "id": 1281,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00414"
    ],
    "proposition_id": 145,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00414:b"
  },
  {
    "id": 1282,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00525"
    ],
    "proposition_id": 375,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00525:a"
  },
  {
    "id": 1283,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00525"
    ],
    "proposition_id": 376,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00525:a"
  },
  {
    "id": 1284,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00525"
    ],
    "proposition_id": 377,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00525:a"
  },
  {
    "id": 1285,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00525"
    ],
    "proposition_id": 375,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00525:b"
  },
  {
    "id": 1286,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00525"
    ],
    "proposition_id": 376,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00525:b"
  },
  {
    "id": 1287,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00525"
    ],
    "proposition_id": 377,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00525:b"
  },
  {
    "id": 1288,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00525"
    ],
    "proposition_id": 140,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00525:b"
  },
  {
    "id": 1289,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00525"
    ],
    "proposition_id": 141,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00525:b"
  },
  {
    "id": 1290,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00525"
    ],
    "proposition_id": 142,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00525:b"
  },
  {
    "id": 1291,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00537"
    ],
    "proposition_id": 168,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00537:a"
  },
  {
    "id": 1292,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00537"
    ],
    "proposition_id": 543,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00537:a"
  },
  {
    "id": 1293,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.P0567"
    ],
    "proposition_id": 46,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.P0567:a"
  },
  {
    "id": 1294,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00530"
    ],
    "proposition_id": 757,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00530:a"
  },
  {
    "id": 1295,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00350"
    ],
    "proposition_id": 352,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00350:a"
  },
  {
    "id": 1296,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00350"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00350:a"
  },
  {
    "id": 1297,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00612"
    ],
    "proposition_id": 758,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00612:a"
  },
  {
    "id": 1298,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00568"
    ],
    "proposition_id": 316,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00568:a"
  },
  {
    "id": 1299,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00569"
    ],
    "proposition_id": 317,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00569:a"
  },
  {
    "id": 1300,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00576"
    ],
    "proposition_id": 584,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00576:a"
  },
  {
    "id": 1301,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00544"
    ],
    "proposition_id": 36,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": NaN
  },
  {
    "id": 1302,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00544"
    ],
    "proposition_id": 37,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": NaN
  },
  {
    "id": 1303,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00544"
    ],
    "proposition_id": 671,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00544:c"
  },
  {
    "id": 1304,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00544"
    ],
    "proposition_id": 672,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00544:d"
  },
  {
    "id": 1305,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00544"
    ],
    "proposition_id": 678,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00544:d"
  },
  {
    "id": 1306,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00544"
    ],
    "proposition_id": 672,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00544:e"
  },
  {
    "id": 1307,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00659"
    ],
    "proposition_id": 20,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00659:a"
  },
  {
    "id": 1308,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00705"
    ],
    "proposition_id": 596,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00705:a"
  },
  {
    "id": 1309,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00706"
    ],
    "proposition_id": 597,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00706:a"
  },
  {
    "id": 1310,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00712"
    ],
    "proposition_id": 174,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00712:a"
  },
  {
    "id": 1311,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00713"
    ],
    "proposition_id": 172,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00713:a"
  },
  {
    "id": 1312,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00714"
    ],
    "proposition_id": 173,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00714:a"
  },
  {
    "id": 1313,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00688"
    ],
    "proposition_id": 679,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00688:a"
  },
  {
    "id": 1314,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00590"
    ],
    "proposition_id": 46,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00590:a"
  },
  {
    "id": 1315,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.P00707"
    ],
    "proposition_id": 46,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.P00707:a"
  },
  {
    "id": 1316,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00790"
    ],
    "proposition_id": 759,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00790:a"
  },
  {
    "id": 1317,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00234"
    ],
    "proposition_id": 534,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00234:d"
  },
  {
    "id": 1318,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00234"
    ],
    "proposition_id": 533,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00234:e"
  },
  {
    "id": 1319,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00234"
    ],
    "proposition_id": 533,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00234:a"
  },
  {
    "id": 1320,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00234"
    ],
    "proposition_id": 533,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00234:b"
  },
  {
    "id": 1321,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00528"
    ],
    "proposition_id": 760,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00528:a"
  },
  {
    "id": 1322,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00739"
    ],
    "proposition_id": 606,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00739:a"
  },
  {
    "id": 1323,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00739"
    ],
    "proposition_id": 761,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00739:a"
  },
  {
    "id": 1324,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00832"
    ],
    "proposition_id": 643,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00832:a"
  },
  {
    "id": 1325,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00593"
    ],
    "proposition_id": 36,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": NaN
  },
  {
    "id": 1326,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00593"
    ],
    "proposition_id": 37,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": NaN
  },
  {
    "id": 1327,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00593"
    ],
    "proposition_id": 671,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00593:c"
  },
  {
    "id": 1328,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00593"
    ],
    "proposition_id": 672,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00593:d"
  },
  {
    "id": 1329,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00593"
    ],
    "proposition_id": 678,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00593:d"
  },
  {
    "id": 1330,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00593"
    ],
    "proposition_id": 672,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00594:f"
  },
  {
    "id": 1331,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00839"
    ],
    "proposition_id": 762,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00839:a"
  },
  {
    "id": 1332,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00538"
    ],
    "proposition_id": 763,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00538:a"
  },
  {
    "id": 1333,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00797"
    ],
    "proposition_id": 764,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00797:a"
  },
  {
    "id": 1334,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00507"
    ],
    "proposition_id": 764,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00507:a"
  },
  {
    "id": 1335,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00796"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00796:a"
  },
  {
    "id": 1336,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00204"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00204:a"
  },
  {
    "id": 1337,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00798"
    ],
    "proposition_id": 765,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00798:a"
  },
  {
    "id": 1338,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00526"
    ],
    "proposition_id": 765,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00526:a"
  },
  {
    "id": 1339,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00785"
    ],
    "proposition_id": 766,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00785:a"
  },
  {
    "id": 1340,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00722"
    ],
    "proposition_id": 360,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00722:a"
  },
  {
    "id": 1341,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00849"
    ],
    "proposition_id": 638,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00849:a"
  },
  {
    "id": 1342,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00849"
    ],
    "proposition_id": 767,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00849:a"
  },
  {
    "id": 1343,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00849"
    ],
    "proposition_id": 640,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00849:a"
  },
  {
    "id": 1344,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00849"
    ],
    "proposition_id": 639,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00849:a"
  },
  {
    "id": 1345,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00849"
    ],
    "proposition_id": 768,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00849:a"
  },
  {
    "id": 1346,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00858"
    ],
    "proposition_id": 345,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00858:a"
  },
  {
    "id": 1347,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00200"
    ],
    "proposition_id": 418,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00200:a"
  },
  {
    "id": 1348,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00200"
    ],
    "proposition_id": 418,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00200:b"
  },
  {
    "id": 1349,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00212"
    ],
    "proposition_id": 769,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00212:c"
  },
  {
    "id": 1350,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00215"
    ],
    "proposition_id": 769,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00215:e"
  },
  {
    "id": 1351,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00215"
    ],
    "proposition_id": 770,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00215:g"
  },
  {
    "id": 1352,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00217"
    ],
    "proposition_id": 195,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00217:a"
  },
  {
    "id": 1353,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00253"
    ],
    "proposition_id": 772,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00253:a"
  },
  {
    "id": 1354,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00253"
    ],
    "proposition_id": 772,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00253:b"
  },
  {
    "id": 1355,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00254"
    ],
    "proposition_id": 773,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00254:a"
  },
  {
    "id": 1356,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00254"
    ],
    "proposition_id": 774,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00254:a"
  },
  {
    "id": 1357,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00254"
    ],
    "proposition_id": 775,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00254:a"
  },
  {
    "id": 1358,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00254"
    ],
    "proposition_id": 773,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00254:b"
  },
  {
    "id": 1359,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00254"
    ],
    "proposition_id": 774,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00254:b"
  },
  {
    "id": 1360,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00254"
    ],
    "proposition_id": 775,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00254:b"
  },
  {
    "id": 1361,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00272"
    ],
    "proposition_id": 418,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00272:a"
  },
  {
    "id": 1362,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00272"
    ],
    "proposition_id": 561,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00272:b"
  },
  {
    "id": 1363,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00272"
    ],
    "proposition_id": 549,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00272:c"
  },
  {
    "id": 1364,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00272"
    ],
    "proposition_id": 776,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00272:d"
  },
  {
    "id": 1365,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00272"
    ],
    "proposition_id": 777,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00272:d"
  },
  {
    "id": 1366,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00272"
    ],
    "proposition_id": 778,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00272:d"
  },
  {
    "id": 1367,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00285"
    ],
    "proposition_id": 418,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00285:a"
  },
  {
    "id": 1368,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00285"
    ],
    "proposition_id": 561,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00285:b"
  },
  {
    "id": 1369,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00285"
    ],
    "proposition_id": 549,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00285:b"
  },
  {
    "id": 1370,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00285"
    ],
    "proposition_id": 563,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00285:c"
  },
  {
    "id": 1371,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00285"
    ],
    "proposition_id": 564,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00285:d"
  },
  {
    "id": 1372,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00361"
    ],
    "proposition_id": 783,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00361:a"
  },
  {
    "id": 1373,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00361"
    ],
    "proposition_id": 783,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00361:b"
  },
  {
    "id": 1374,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00371"
    ],
    "proposition_id": 784,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00317:a"
  },
  {
    "id": 1375,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00371"
    ],
    "proposition_id": 785,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00317:a"
  },
  {
    "id": 1376,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00371"
    ],
    "proposition_id": 786,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00317:a"
  },
  {
    "id": 1377,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00371"
    ],
    "proposition_id": 784,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00317:d"
  },
  {
    "id": 1378,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00371"
    ],
    "proposition_id": 785,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00317:d"
  },
  {
    "id": 1379,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00371"
    ],
    "proposition_id": 786,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00317:d"
  },
  {
    "id": 1380,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00376"
    ],
    "proposition_id": 787,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00376:a"
  },
  {
    "id": 1381,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00376"
    ],
    "proposition_id": 788,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00376:a"
  },
  {
    "id": 1382,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00376"
    ],
    "proposition_id": 789,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00376:a"
  },
  {
    "id": 1383,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00430"
    ],
    "proposition_id": 790,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00430:a"
  },
  {
    "id": 1384,
    "type": "Statement",
    "description": "",
    "contributions": [
      111,
      113
    ],
    "reportedIn": [
      "doc:hse.00619"
    ],
    "proposition_id": 792,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00619:a"
  },
  {
    "id": 1385,
    "type": "Statement",
    "description": "",
    "contributions": [
      111,
      113
    ],
    "reportedIn": [
      "doc:hse.00619"
    ],
    "proposition_id": 793,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00619:a"
  },
  {
    "id": 1386,
    "type": "Statement",
    "description": "",
    "contributions": [
      111,
      113
    ],
    "reportedIn": [
      "doc:hse.00619"
    ],
    "proposition_id": 794,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00619:a"
  },
  {
    "id": 1387,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00726"
    ],
    "proposition_id": 766,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00726:a"
  },
  {
    "id": 1388,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00731"
    ],
    "proposition_id": 360,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00731:a"
  },
  {
    "id": 1389,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00775"
    ],
    "proposition_id": 759,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00775:a"
  },
  {
    "id": 1390,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00789"
    ],
    "proposition_id": 360,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00789:a"
  },
  {
    "id": 1391,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00857"
    ],
    "proposition_id": 345,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00857:a"
  },
  {
    "id": 1392,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00225"
    ],
    "proposition_id": 692,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00225:c"
  },
  {
    "id": 1393,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00328"
    ],
    "proposition_id": 797,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00328:a"
  },
  {
    "id": 1394,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00816"
    ],
    "proposition_id": 643,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00816:a"
  },
  {
    "id": 1395,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00844"
    ],
    "proposition_id": 800,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00844:a"
  },
  {
    "id": 1396,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00558"
    ],
    "proposition_id": 588,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00558:a"
  },
  {
    "id": 1397,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00558"
    ],
    "proposition_id": 595,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00558:f"
  },
  {
    "id": 1398,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00558"
    ],
    "proposition_id": 320,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00558:h"
  },
  {
    "id": 1399,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00558"
    ],
    "proposition_id": 339,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00558:j"
  },
  {
    "id": 1400,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00558"
    ],
    "proposition_id": 324,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00558:k"
  },
  {
    "id": 1401,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00811"
    ],
    "proposition_id": 337,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00811:a"
  },
  {
    "id": 1402,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00817"
    ],
    "proposition_id": 335,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00817:a"
  },
  {
    "id": 1403,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00661"
    ],
    "proposition_id": 804,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00661:a"
  },
  {
    "id": 1404,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00683"
    ],
    "proposition_id": 804,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00683:a"
  },
  {
    "id": 1405,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00281"
    ],
    "proposition_id": 640,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00281:b"
  },
  {
    "id": 1406,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00304"
    ],
    "proposition_id": 638,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00304:c"
  },
  {
    "id": 1407,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00310"
    ],
    "proposition_id": 767,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00310:c"
  },
  {
    "id": 1408,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00317"
    ],
    "proposition_id": 768,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00317:c"
  },
  {
    "id": 1409,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00318"
    ],
    "proposition_id": 639,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00318:c"
  },
  {
    "id": 1410,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00592"
    ],
    "proposition_id": 671,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00592:c"
  },
  {
    "id": 1411,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00592"
    ],
    "proposition_id": 672,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00592:d"
  },
  {
    "id": 1412,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00592"
    ],
    "proposition_id": 678,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00592:d"
  },
  {
    "id": 1413,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00592"
    ],
    "proposition_id": 672,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00592:e"
  },
  {
    "id": 1414,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00655"
    ],
    "proposition_id": 584,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00655:a"
  },
  {
    "id": 1415,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00307"
    ],
    "proposition_id": 380,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00307:a"
  },
  {
    "id": 1416,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00397"
    ],
    "proposition_id": 812,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00397:a"
  },
  {
    "id": 1417,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00409"
    ],
    "proposition_id": 813,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00409:a"
  },
  {
    "id": 1418,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00436"
    ],
    "proposition_id": 813,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00436:a"
  },
  {
    "id": 1419,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00506"
    ],
    "proposition_id": 814,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00506:a"
  },
  {
    "id": 1420,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00506"
    ],
    "proposition_id": 815,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00506:a"
  },
  {
    "id": 1421,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00510"
    ],
    "proposition_id": 816,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00510:a"
  },
  {
    "id": 1422,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00529"
    ],
    "proposition_id": 817,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00529:a"
  },
  {
    "id": 1423,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00542"
    ],
    "proposition_id": 818,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00542:a"
  },
  {
    "id": 1424,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00542"
    ],
    "proposition_id": 819,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00542:a"
  },
  {
    "id": 1425,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00542"
    ],
    "proposition_id": 820,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00542:a"
  },
  {
    "id": 1426,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00542"
    ],
    "proposition_id": 821,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00542:a"
  },
  {
    "id": 1427,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00543"
    ],
    "proposition_id": 822,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00543:a"
  },
  {
    "id": 1428,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00543"
    ],
    "proposition_id": 378,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00543:a"
  },
  {
    "id": 1429,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00599"
    ],
    "proposition_id": 822,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00599:a"
  },
  {
    "id": 1430,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00599"
    ],
    "proposition_id": 378,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00599:a"
  },
  {
    "id": 1431,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00600"
    ],
    "proposition_id": 822,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00600:a"
  },
  {
    "id": 1432,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00600"
    ],
    "proposition_id": 378,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00600:a"
  },
  {
    "id": 1433,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00672"
    ],
    "proposition_id": 810,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00672:a"
  },
  {
    "id": 1434,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00672"
    ],
    "proposition_id": 811,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00672:a"
  },
  {
    "id": 1435,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00293"
    ],
    "proposition_id": 379,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00293:a"
  },
  {
    "id": 1436,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00293"
    ],
    "proposition_id": 379,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00293:b"
  },
  {
    "id": 1437,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00540"
    ],
    "proposition_id": 822,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00540:a"
  },
  {
    "id": 1438,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00540"
    ],
    "proposition_id": 378,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00540:a"
  },
  {
    "id": 1439,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00335"
    ],
    "proposition_id": 165,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00335:a"
  },
  {
    "id": 1440,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00335"
    ],
    "proposition_id": 165,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00335:b"
  },
  {
    "id": 1441,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00823"
    ],
    "proposition_id": 414,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00823:a"
  },
  {
    "id": 1442,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00823"
    ],
    "proposition_id": 415,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00823:a"
  },
  {
    "id": 1443,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00776"
    ],
    "proposition_id": 420,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00776:a"
  },
  {
    "id": 1444,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00860"
    ],
    "proposition_id": 345,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00860:a"
  },
  {
    "id": 1445,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00861"
    ],
    "proposition_id": 345,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00861:a"
  },
  {
    "id": 1446,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00242"
    ],
    "proposition_id": 547,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00242:a"
  },
  {
    "id": 1447,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00356"
    ],
    "proposition_id": 28,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00356:a"
  },
  {
    "id": 1448,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00356"
    ],
    "proposition_id": 28,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00356:b"
  },
  {
    "id": 1449,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00794"
    ],
    "proposition_id": 403,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00794:a"
  },
  {
    "id": 1450,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00702"
    ],
    "proposition_id": 121,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00702:b"
  },
  {
    "id": 1451,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00702"
    ],
    "proposition_id": 122,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00702:b"
  },
  {
    "id": 1452,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00702"
    ],
    "proposition_id": 123,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00702:b"
  },
  {
    "id": 1453,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00254"
    ],
    "proposition_id": 824,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00254:c"
  },
  {
    "id": 1454,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00254"
    ],
    "proposition_id": 825,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00254:c"
  },
  {
    "id": 1455,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00254"
    ],
    "proposition_id": 826,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00254:c"
  },
  {
    "id": 1456,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00371"
    ],
    "proposition_id": 785,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00371:b"
  },
  {
    "id": 1457,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00371"
    ],
    "proposition_id": 786,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00371:b"
  },
  {
    "id": 1458,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00371"
    ],
    "proposition_id": 784,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00371:b"
  },
  {
    "id": 1459,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00371"
    ],
    "proposition_id": 785,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00371:d"
  },
  {
    "id": 1460,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00371"
    ],
    "proposition_id": 786,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00371:d"
  },
  {
    "id": 1461,
    "type": "Statement",
    "description": "",
    "contributions": [
      41
    ],
    "reportedIn": [
      "doc:hse.00371"
    ],
    "proposition_id": 784,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00371:d"
  },
  {
    "id": 1462,
    "type": "Statement",
    "description": "",
    "contributions": [
      111,
      113
    ],
    "reportedIn": [
      "doc:hse.00619"
    ],
    "proposition_id": 0,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00619:a"
  },
  {
    "id": 1463,
    "type": "Statement",
    "description": "",
    "contributions": [
      111,
      113
    ],
    "reportedIn": [
      "doc:hse.00619"
    ],
    "proposition_id": 1,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00619:a"
  },
  {
    "id": 1464,
    "type": "Statement",
    "description": "",
    "contributions": [
      111,
      113
    ],
    "reportedIn": [
      "doc:hse.00619"
    ],
    "proposition_id": 2,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00619:a"
  },
  {
    "id": 1465,
    "type": "Statement",
    "description": "",
    "contributions": [
      111,
      113
    ],
    "reportedIn": [
      "doc:hse.00619"
    ],
    "proposition_id": 8,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00619:a"
  },
  {
    "id": 1466,
    "type": "Statement",
    "description": "",
    "contributions": [
      111,
      113
    ],
    "reportedIn": [
      "doc:hse.00619"
    ],
    "proposition_id": 6,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00619:a"
  },
  {
    "id": 1467,
    "type": "Statement",
    "description": "",
    "contributions": [
      111,
      113
    ],
    "reportedIn": [
      "doc:hse.00619"
    ],
    "proposition_id": 7,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00619:a"
  },
  {
    "id": 1468,
    "type": "Statement",
    "description": "",
    "contributions": [
      111,
      113
    ],
    "reportedIn": [
      "doc:hse.00619"
    ],
    "proposition_id": 3,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00619:a"
  },
  {
    "id": 1469,
    "type": "Statement",
    "description": "",
    "contributions": [
      111,
      113
    ],
    "reportedIn": [
      "doc:hse.00619"
    ],
    "proposition_id": 4,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00619:a"
  },
  {
    "id": 1470,
    "type": "Statement",
    "description": "",
    "contributions": [
      111,
      113
    ],
    "reportedIn": [
      "doc:hse.00619"
    ],
    "proposition_id": 5,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hse.00619:a"
  }


  {
    "id": 1471,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive advanced breast cancer.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.arimidex"
    ],
    "proposition_id": 824,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.arimidex:0"
  },
  {
    "id": 1472,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive advanced breast cancer.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.arimidex"
    ],
    "proposition_id": 825,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.arimidex:0"
  },
  {
    "id": 1472,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive advanced breast cancer.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.arimidex"
    ],
    "proposition_id": 826,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.arimidex:0"
  },
  {
    "id": 1473,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.arimidex"
    ],
    "proposition_id": 824,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.arimidex:1"
  },
  {
    "id": 1474,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.arimidex"
    ],
    "proposition_id": 825,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.arimidex:1"
  },
  {
    "id": 1475,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.arimidex"
    ],
    "proposition_id": 826,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.arimidex:1"
  },
  {
    "id": 1476,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.arimidex"
    ],
    "proposition_id": 824,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.arimidex:2"
  },
  {
    "id": 1477,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.arimidex"
    ],
    "proposition_id": 825,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.arimidex:2"
  },
  {
    "id": 1478,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.arimidex"
    ],
    "proposition_id": 826,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.arimidex:2"
  },
  {
    "id": 1479,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized exemestane for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive invasive early breast cancer (EBC) who have received 2 to 3 years of initial tamoxifen therapy.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.aromasin"
    ],
    "proposition_id": 788,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.aromasin:0"
  },
  {
    "id": 1480,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor positive invasive early breast cancer.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.femara"
    ],
    "proposition_id": 785,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.femara:0"
  },
  {
    "id": 1481,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor positive invasive early breast cancer.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.femara"
    ],
    "proposition_id": 786,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.femara:0"
  },
  {
    "id": 1482,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor positive invasive early breast cancer.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.femara"
    ],
    "proposition_id": 784,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.femara:0"
  },
  {
    "id": 1483,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior standard adjuvant tamoxifen therapy for 5 years.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.femara"
    ],
    "proposition_id": 785,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.femara:1"
  },
  {
    "id": 1484,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior standard adjuvant tamoxifen therapy for 5 years.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.femara"
    ],
    "proposition_id": 786,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.femara:1"
  },
  {
    "id": 1485,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior standard adjuvant tamoxifen therapy for 5 years.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.femara"
    ],
    "proposition_id": 784,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.femara:1"
  },
  {
    "id": 1486,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the first-line treatment of patients who are postmenopausal women with hormone-dependent advanced breast cancer.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.femara"
    ],
    "proposition_id": 785,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.femara:2"
  },
  {
    "id": 1487,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the first-line treatment of patients who are postmenopausal women with hormone-dependent advanced breast cancer.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.femara"
    ],
    "proposition_id": 786,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.femara:2"
  },
  {
    "id": 1488,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the first-line treatment of patients who are postmenopausal women with hormone-dependent advanced breast cancer.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.femara"
    ],
    "proposition_id": 784,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.femara:2"
  },
  {
    "id": 1489,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the neo-adjuvant treatment of patients who are postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery is not indicated.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.femara"
    ],
    "proposition_id": 827,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.femara:3"
  },
  {
    "id": 1490,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the neo-adjuvant treatment of patients who are postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery is not indicated.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.femara"
    ],
    "proposition_id": 828,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.femara:3"
  },
  {
    "id": 1491,
    "type": "Statement",
    "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the neo-adjuvant treatment of patients who are postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery is not indicated.",
    "contributions": [
      42
    ],
    "reportedIn": [
      "doc:hpra.femara"
    ],
    "proposition_id": 829,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hpra.femara:3"
  },
  {
    "id": 2000,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.adcetris"
    ],
    "proposition_id": 48,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.adcetris:0"
  },
  {
    "id": 2001,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.adcetris"
    ],
    "proposition_id": 847,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.adcetris:0"
  },
  {
    "id": 2002,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.adcetris"
    ],
    "proposition_id": 848,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.adcetris:0"
  },
  {
    "id": 2003,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.adcetris"
    ],
    "proposition_id": 841,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.adcetris:1"
  },
  {
    "id": 2004,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.afinitor"
    ],
    "proposition_id": 131,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.afinitor:0"
  },
  {
    "id": 2005,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.afinitor"
    ],
    "proposition_id": 132,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.afinitor:0"
  },
  {
    "id": 2006,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.afinitor"
    ],
    "proposition_id": 133,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.afinitor:0"
  },
  {
    "id": 2007,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.alecensaro"
    ],
    "proposition_id": 22,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.alecensaro:0"
  },
  {
    "id": 2008,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.alunbrig"
    ],
    "proposition_id": 50,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.alunbrig:0"
  },
  {
    "id": 2009,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.augtyro"
    ],
    "proposition_id": 368,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.augtyro:0"
  },
  {
    "id": 2010,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.balversa"
    ],
    "proposition_id": 124,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.balversa:0"
  },
  {
    "id": 2011,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.balversa"
    ],
    "proposition_id": 125,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.balversa:0"
  },
  {
    "id": 2012,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.balversa"
    ],
    "proposition_id": 126,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.balversa:0"
  },
  {
    "id": 2013,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.balversa"
    ],
    "proposition_id": 127,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.balversa:0"
  },
  {
    "id": 2014,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.balversa"
    ],
    "proposition_id": 128,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.balversa:0"
  },
  {
    "id": 2015,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.besponsa"
    ],
    "proposition_id": 168,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.besponsa:0"
  },
  {
    "id": 2016,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.blincyto"
    ],
    "proposition_id": 45,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.blincyto:2"
  },
  {
    "id": 2017,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.bosulif"
    ],
    "proposition_id": 47,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.bosulif:0"
  },
  {
    "id": 2018,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.bosulif"
    ],
    "proposition_id": 47,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.bosulif:1"
  },
  {
    "id": 2019,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.braftovi"
    ],
    "proposition_id": 41,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.braftovi:0"
  },
  {
    "id": 2020,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.braftovi"
    ],
    "proposition_id": 81,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.braftovi:1"
  },
  {
    "id": 2021,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.cotellic"
    ],
    "proposition_id": 82,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.cotellic:0"
  },
  {
    "id": 2022,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.cotellic"
    ],
    "proposition_id": 83,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.cotellic:0"
  },
  {
    "id": 2023,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.enhertu"
    ],
    "proposition_id": 420,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.enhertu:0"
  },
  {
    "id": 2024,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.enhertu"
    ],
    "proposition_id": 420,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.enhertu:1"
  },
  {
    "id": 2025,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.enhertu"
    ],
    "proposition_id": 421,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.enhertu:0"
  },
  {
    "id": 2026,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.enhertu"
    ],
    "proposition_id": 423,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.enhertu:3"
  },
  {
    "id": 2027,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.erbitux"
    ],
    "proposition_id": 78,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.erbitux:0"
  },
  {
    "id": 2028,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.erbitux"
    ],
    "proposition_id": 79,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.erbitux:1"
  },
  {
    "id": 2029,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.erbitux"
    ],
    "proposition_id": 80,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.erbitux:2"
  },
  {
    "id": 2030,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.erbitux"
    ],
    "proposition_id": 80,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.erbitux:3"
  },
  {
    "id": 2031,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.faslodex"
    ],
    "proposition_id": 134,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.faslodex:0"
  },
  {
    "id": 2032,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.giotrif"
    ],
    "proposition_id": 21,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.giotrif:0"
  },
  {
    "id": 2033,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.giotrif"
    ],
    "proposition_id": 560,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.giotrif:0"
  },
  {
    "id": 2034,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.gleevec"
    ],
    "proposition_id": 158,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.gleevec:0"
  },
  {
    "id": 2035,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.gleevec"
    ],
    "proposition_id": 158,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.gleevec:1"
  },
  {
    "id": 2036,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.gleevec"
    ],
    "proposition_id": 160,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.gleevec:2"
  },
  {
    "id": 2037,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.gleevec"
    ],
    "proposition_id": 160,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.gleevec:3"
  },
  {
    "id": 2038,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.gleevec"
    ],
    "proposition_id": 161,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.gleevec:4"
  },
  {
    "id": 2039,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.gleevec"
    ],
    "proposition_id": 162,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.gleevec:4"
  },
  {
    "id": 2040,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.gleevec"
    ],
    "proposition_id": 580,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.gleevec:4"
  },
  {
    "id": 2041,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.gleevec"
    ],
    "proposition_id": 581,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.gleevec:4"
  },
  {
    "id": 2042,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.gleevec"
    ],
    "proposition_id": 163,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.gleevec:5"
  },
  {
    "id": 2043,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.gleevec"
    ],
    "proposition_id": 164,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.gleevec:6"
  },
  {
    "id": 2044,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.gleevec"
    ],
    "proposition_id": 165,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.gleevec:7"
  },
  {
    "id": 2045,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.gleevec"
    ],
    "proposition_id": 165,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.gleevec:8"
  },
  {
    "id": 2046,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.herceptin"
    ],
    "proposition_id": 418,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.herceptin:0"
  },
  {
    "id": 2047,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.herceptin"
    ],
    "proposition_id": 842,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.herceptin:1"
  },
  {
    "id": 2048,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.herceptin"
    ],
    "proposition_id": 563,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.herceptin:2"
  },
  {
    "id": 2049,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.herceptin"
    ],
    "proposition_id": 418,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.herceptin:3"
  },
  {
    "id": 2050,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.herceptin"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.herceptin:4"
  },
  {
    "id": 2051,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.ibrance"
    ],
    "proposition_id": 311,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.ibrance:0"
  },
  {
    "id": 2052,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.ibrance"
    ],
    "proposition_id": 312,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.ibrance:0"
  },
  {
    "id": 2053,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.ibrance"
    ],
    "proposition_id": 313,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.ibrance:0"
  },
  {
    "id": 2054,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.ibrance"
    ],
    "proposition_id": 143,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.ibrance:1"
  },
  {
    "id": 2055,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.ibrance"
    ],
    "proposition_id": 144,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.ibrance:1"
  },
  {
    "id": 2056,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.ibrance"
    ],
    "proposition_id": 145,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.ibrance:1"
  },
  {
    "id": 2057,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.iclusig"
    ],
    "proposition_id": 363,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.iclusig:0"
  },
  {
    "id": 2058,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.iclusig"
    ],
    "proposition_id": 362,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.iclusig:1"
  },
  {
    "id": 2059,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.imfinzi"
    ],
    "proposition_id": 585,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.imfinzi:0"
  },
  {
    "id": 2060,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.imfinzi"
    ],
    "proposition_id": 109,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.imfinzi:1"
  },
  {
    "id": 2061,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.iressa"
    ],
    "proposition_id": 147,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.iressa:0"
  },
  {
    "id": 2062,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.iressa"
    ],
    "proposition_id": 148,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.iressa:0"
  },
  {
    "id": 2063,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.iressa"
    ],
    "proposition_id": 559,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.iressa:0"
  },
  {
    "id": 2064,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.itovebi"
    ],
    "proposition_id": 510,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.itovebi:0"
  },
  {
    "id": 2065,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.itovebi"
    ],
    "proposition_id": 511,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.itovebi:0"
  },
  {
    "id": 2066,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.itovebi"
    ],
    "proposition_id": 512,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.itovebi:0"
  },
  {
    "id": 2067,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.jemperli"
    ],
    "proposition_id": 102,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.jemperli:0"
  },
  {
    "id": 2068,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.jemperli"
    ],
    "proposition_id": 587,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.jemperli:0"
  },
  {
    "id": 2069,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.kadcyla"
    ],
    "proposition_id": 20,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.kadcyla:0"
  },
  {
    "id": 2070,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.kadcyla"
    ],
    "proposition_id": 20,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.kadcyla:1"
  },
  {
    "id": 2071,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 843,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:0"
  },
  {
    "id": 2072,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 844,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:0"
  },
  {
    "id": 2073,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 318,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:1"
  },
  {
    "id": 2074,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 319,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:3"
  },
  {
    "id": 2075,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 323,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:4"
  },
  {
    "id": 2076,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 324,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:4"
  },
  {
    "id": 2077,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 321,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:5"
  },
  {
    "id": 2078,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 322,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:5"
  },
  {
    "id": 2079,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 320,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:7"
  },
  {
    "id": 2080,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 325,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:8"
  },
  {
    "id": 2081,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 327,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:9"
  },
  {
    "id": 2082,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 346,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:10"
  },
  {
    "id": 2083,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 333,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:11"
  },
  {
    "id": 2084,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 334,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:11"
  },
  {
    "id": 2085,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 337,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:11"
  },
  {
    "id": 2086,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.keytruda"
    ],
    "proposition_id": 338,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.keytruda:11"
  },
  {
    "id": 2087,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.kisqali"
    ],
    "proposition_id": 372,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.kisqali:0"
  },
  {
    "id": 2088,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.kisqali"
    ],
    "proposition_id": 373,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.kisqali:0"
  },
  {
    "id": 2089,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.kisqali"
    ],
    "proposition_id": 374,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.kisqali:0"
  },
  {
    "id": 2090,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.kisqali"
    ],
    "proposition_id": 375,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.kisqali:0"
  },
  {
    "id": 2091,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.kisqali"
    ],
    "proposition_id": 376,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.kisqali:0"
  },
  {
    "id": 2092,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.kisqali"
    ],
    "proposition_id": 377,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.kisqali:0"
  },
  {
    "id": 2093,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.kisqali"
    ],
    "proposition_id": 140,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.kisqali:1"
  },
  {
    "id": 2094,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.kisqali"
    ],
    "proposition_id": 141,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.kisqali:1"
  },
  {
    "id": 2095,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.kisqali"
    ],
    "proposition_id": 142,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.kisqali:1"
  },
  {
    "id": 2096,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lazcluze"
    ],
    "proposition_id": 463,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lazcluze:0"
  },
  {
    "id": 2097,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lazcluze"
    ],
    "proposition_id": 464,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lazcluze:0"
  },
  {
    "id": 2098,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.libtayo"
    ],
    "proposition_id": 618,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.libtayo:0"
  },
  {
    "id": 2099,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.libtayo"
    ],
    "proposition_id": 75,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.libtayo:0"
  },
  {
    "id": 2100,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lorbrena"
    ],
    "proposition_id": 203,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lorbrena:0"
  },
  {
    "id": 2101,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lorbrena"
    ],
    "proposition_id": 203,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lorbrena:1"
  },
  {
    "id": 2102,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lumakras"
    ],
    "proposition_id": 411,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lumakras:0"
  },
  {
    "id": 2103,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 258,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:0"
  },
  {
    "id": 2104,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 259,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:0"
  },
  {
    "id": 2105,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 258,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:1"
  },
  {
    "id": 2106,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 259,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:1"
  },
  {
    "id": 2107,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 231,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:2"
  },
  {
    "id": 2108,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 232,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:2"
  },
  {
    "id": 2109,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 233,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:2"
  },
  {
    "id": 2110,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 234,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:2"
  },
  {
    "id": 2111,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 235,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:2"
  },
  {
    "id": 2112,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 236,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:2"
  },
  {
    "id": 2113,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 237,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:2"
  },
  {
    "id": 2114,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 238,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:2"
  },
  {
    "id": 2115,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 239,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:2"
  },
  {
    "id": 2116,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 240,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:2"
  },
  {
    "id": 2117,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 241,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:2"
  },
  {
    "id": 2118,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 242,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:2"
  },
  {
    "id": 2119,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 243,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:3"
  },
  {
    "id": 2120,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 244,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:3"
  },
  {
    "id": 2121,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 245,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:3"
  },
  {
    "id": 2122,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 246,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:3"
  },
  {
    "id": 2123,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 248,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:3"
  },
  {
    "id": 2124,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 249,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:3"
  },
  {
    "id": 2125,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 250,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:3"
  },
  {
    "id": 2126,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 251,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:3"
  },
  {
    "id": 2127,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 253,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:3"
  },
  {
    "id": 2128,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 254,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:3"
  },
  {
    "id": 2129,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 255,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:3"
  },
  {
    "id": 2130,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 256,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:3"
  },
  {
    "id": 2131,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 260,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:4"
  },
  {
    "id": 2132,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 261,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:4"
  },
  {
    "id": 2133,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 263,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:5"
  },
  {
    "id": 2134,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 264,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:5"
  },
  {
    "id": 2135,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 265,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:5"
  },
  {
    "id": 2136,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 266,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:5"
  },
  {
    "id": 2137,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 267,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:5"
  },
  {
    "id": 2138,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 268,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:5"
  },
  {
    "id": 2139,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 291,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:6"
  },
  {
    "id": 2140,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 292,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:6"
  },
  {
    "id": 2141,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 293,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:6"
  },
  {
    "id": 2142,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 294,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:6"
  },
  {
    "id": 2143,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 295,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:6"
  },
  {
    "id": 2144,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 296,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:6"
  },
  {
    "id": 2145,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 297,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:6"
  },
  {
    "id": 2146,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.lynparza"
    ],
    "proposition_id": 298,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.lynparza:6"
  },
  {
    "id": 2147,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.mekinist"
    ],
    "proposition_id": 417,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.mekinist:0"
  },
  {
    "id": 2148,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.mekinist"
    ],
    "proposition_id": 416,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.mekinist:0"
  },
  {
    "id": 2149,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.mekinist"
    ],
    "proposition_id": 91,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.mekinist:2"
  },
  {
    "id": 2150,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.mekinist"
    ],
    "proposition_id": 94,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.mekinist:3"
  },
  {
    "id": 2151,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.mekinist"
    ],
    "proposition_id": 660,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.mekinist:0"
  },
  {
    "id": 2152,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.mektovi"
    ],
    "proposition_id": 41,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.mektovi:0"
  },
  {
    "id": 2153,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.mektovi"
    ],
    "proposition_id": 42,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.mektovi:0"
  },
  {
    "id": 2154,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.mylotarg"
    ],
    "proposition_id": 628,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.mylotarg:0"
  },
  {
    "id": 2155,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.nerlynx"
    ],
    "proposition_id": 629,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.nerlynx:0"
  },
  {
    "id": 2156,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.nerlynx"
    ],
    "proposition_id": 630,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.nerlynx:0"
  },
  {
    "id": 2157,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.nerlynx"
    ],
    "proposition_id": 631,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.nerlynx:0"
  },
  {
    "id": 2158,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.nerlynx"
    ],
    "proposition_id": 220,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.nerlynx:1"
  },
  {
    "id": 2159,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.opdivo"
    ],
    "proposition_id": 845,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.opdivo:0"
  },
  {
    "id": 2160,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.opdivo"
    ],
    "proposition_id": 846,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.opdivo:0"
  },
  {
    "id": 2161,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.opdivo"
    ],
    "proposition_id": 171,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.opdivo:2"
  },
  {
    "id": 2162,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.opdivo"
    ],
    "proposition_id": 642,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.opdivo:6"
  },
  {
    "id": 2163,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.opdivo"
    ],
    "proposition_id": 643,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.opdivo:7"
  },
  {
    "id": 2164,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.opdivo"
    ],
    "proposition_id": 800,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.opdivo:7"
  },
  {
    "id": 2165,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.pemazyre"
    ],
    "proposition_id": 348,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.pemazyre:0"
  },
  {
    "id": 2166,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.pemazyre"
    ],
    "proposition_id": 349,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.pemazyre:0"
  },
  {
    "id": 2167,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2168,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 352,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2169,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 353,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2170,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 354,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2171,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 355,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2172,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 356,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2173,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 357,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2174,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 358,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2175,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 359,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2176,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 360,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2177,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 759,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2178,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 764,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2179,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 765,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:0"
  },
  {
    "id": 2180,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.perjeta"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.perjeta:1"
  },
  {
    "id": 2181,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2182,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 352,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2183,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 353,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2184,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 354,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2185,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 355,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2186,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 356,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2187,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 357,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2188,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 358,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2189,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 359,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2190,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 360,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2191,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 759,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2192,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 764,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2193,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 765,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:0"
  },
  {
    "id": 2194,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.phesgo"
    ],
    "proposition_id": 351,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.phesgo:2"
  },
  {
    "id": 2195,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.retevmo"
    ],
    "proposition_id": 407,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.retevmo:0"
  },
  {
    "id": 2196,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.retevmo"
    ],
    "proposition_id": 408,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.retevmo:1"
  },
  {
    "id": 2197,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.retevmo"
    ],
    "proposition_id": 656,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.retevmo:2"
  },
  {
    "id": 2198,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.revlimid"
    ],
    "proposition_id": 202,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.revlimid:0"
  },
  {
    "id": 2199,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rituxan"
    ],
    "proposition_id": 378,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rituxan:0"
  },
  {
    "id": 2200,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rituxan"
    ],
    "proposition_id": 822,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rituxan:0"
  },
  {
    "id": 2201,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rituxan"
    ],
    "proposition_id": 383,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rituxan:1"
  },
  {
    "id": 2202,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rituxan"
    ],
    "proposition_id": 622,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rituxan:1"
  },
  {
    "id": 2203,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rituxan"
    ],
    "proposition_id": 818,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rituxan:2"
  },
  {
    "id": 2204,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rozlytrek"
    ],
    "proposition_id": 121,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rozlytrek:0"
  },
  {
    "id": 2205,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rozlytrek"
    ],
    "proposition_id": 122,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rozlytrek:0"
  },
  {
    "id": 2206,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rozlytrek"
    ],
    "proposition_id": 123,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rozlytrek:0"
  },
  {
    "id": 2207,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rozlytrek"
    ],
    "proposition_id": 120,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rozlytrek:1"
  },
  {
    "id": 2208,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rybrevant"
    ],
    "proposition_id": 465,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rybrevant:0"
  },
  {
    "id": 2209,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rybrevant"
    ],
    "proposition_id": 466,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rybrevant:0"
  },
  {
    "id": 2210,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rybrevant"
    ],
    "proposition_id": 26,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rybrevant:1"
  },
  {
    "id": 2211,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rybrevant"
    ],
    "proposition_id": 27,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rybrevant:2"
  },
  {
    "id": 2212,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rydapt"
    ],
    "proposition_id": 208,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rydapt:0"
  },
  {
    "id": 2213,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rydapt"
    ],
    "proposition_id": 209,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rydapt:0"
  },
  {
    "id": 2214,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rydapt"
    ],
    "proposition_id": 210,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rydapt:0"
  },
  {
    "id": 2215,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rydapt"
    ],
    "proposition_id": 211,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rydapt:0"
  },
  {
    "id": 2216,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rydapt"
    ],
    "proposition_id": 212,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rydapt:0"
  },
  {
    "id": 2217,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rydapt"
    ],
    "proposition_id": 213,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rydapt:0"
  },
  {
    "id": 2218,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rydapt"
    ],
    "proposition_id": 214,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rydapt:0"
  },
  {
    "id": 2219,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rydapt"
    ],
    "proposition_id": 215,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rydapt:0"
  },
  {
    "id": 2220,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.rydapt"
    ],
    "proposition_id": 216,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.rydapt:0"
  },
  {
    "id": 2222,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tabrecta"
    ],
    "proposition_id": 73,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tabrecta:0"
  },
  {
    "id": 2223,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tabrecta"
    ],
    "proposition_id": 74,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tabrecta:0"
  },
  {
    "id": 2224,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tafinlar"
    ],
    "proposition_id": 88,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tafinlar:0"
  },
  {
    "id": 2225,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tafinlar"
    ],
    "proposition_id": 663,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tafinlar:0"
  },
  {
    "id": 2226,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tafinlar"
    ],
    "proposition_id": 91,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tafinlar:2"
  },
  {
    "id": 2227,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tafinlar"
    ],
    "proposition_id": 94,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tafinlar:3"
  },
  {
    "id": 2228,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tafinlar"
    ],
    "proposition_id": 660,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tafinlar:4"
  },
  {
    "id": 2229,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tagrisso"
    ],
    "proposition_id": 304,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tagrisso:0"
  },
  {
    "id": 2230,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tagrisso"
    ],
    "proposition_id": 305,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tagrisso:0"
  },
  {
    "id": 2231,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tagrisso"
    ],
    "proposition_id": 304,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tagrisso:1"
  },
  {
    "id": 2232,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tagrisso"
    ],
    "proposition_id": 305,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tagrisso:1"
  },
  {
    "id": 2233,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tagrisso"
    ],
    "proposition_id": 304,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tagrisso:2"
  },
  {
    "id": 2234,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tagrisso"
    ],
    "proposition_id": 305,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tagrisso:2"
  },
  {
    "id": 2235,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tagrisso"
    ],
    "proposition_id": 306,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tagrisso:3"
  },
  {
    "id": 2236,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tagrisso"
    ],
    "proposition_id": 307,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tagrisso:3"
  },
  {
    "id": 2237,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tagrisso"
    ],
    "proposition_id": 308,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tagrisso:3"
  },
  {
    "id": 2238,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tagrisso"
    ],
    "proposition_id": 309,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tagrisso:3"
  },
  {
    "id": 2239,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tagrisso"
    ],
    "proposition_id": 310,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tagrisso:4"
  },
  {
    "id": 2240,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tecentriq"
    ],
    "proposition_id": 32,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tecentriq:0"
  },
  {
    "id": 2241,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tecentriq"
    ],
    "proposition_id": 672,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tecentriq:1"
  },
  {
    "id": 2242,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tecentriq"
    ],
    "proposition_id": 678,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tecentriq:1"
  },
  {
    "id": 2243,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tecentriq"
    ],
    "proposition_id": 679,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tecentriq:5"
  },
  {
    "id": 2244,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tepmetko"
    ],
    "proposition_id": 414,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tepmetko:0"
  },
  {
    "id": 2245,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tepmetko"
    ],
    "proposition_id": 415,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tepmetko:0"
  },
  {
    "id": 2246,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tibsovo"
    ],
    "proposition_id": 180,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tibsovo:0"
  },
  {
    "id": 2247,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tibsovo"
    ],
    "proposition_id": 181,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tibsovo:0"
  },
  {
    "id": 2248,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tibsovo"
    ],
    "proposition_id": 182,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tibsovo:0"
  },
  {
    "id": 2249,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tibsovo"
    ],
    "proposition_id": 183,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tibsovo:0"
  },
  {
    "id": 2250,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tibsovo"
    ],
    "proposition_id": 184,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tibsovo:0"
  },
  {
    "id": 2251,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tibsovo"
    ],
    "proposition_id": 190,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tibsovo:1"
  },
  {
    "id": 2252,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tibsovo"
    ],
    "proposition_id": 191,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tibsovo:1"
  },
  {
    "id": 2253,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tibsovo"
    ],
    "proposition_id": 192,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tibsovo:1"
  },
  {
    "id": 2254,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tibsovo"
    ],
    "proposition_id": 193,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tibsovo:1"
  },
  {
    "id": 2255,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tibsovo"
    ],
    "proposition_id": 194,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tibsovo:0"
  },
  {
    "id": 2256,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.trodelvy"
    ],
    "proposition_id": 404,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.trodelvy:0"
  },
  {
    "id": 2257,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.trodelvy"
    ],
    "proposition_id": 405,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.trodelvy:0"
  },
  {
    "id": 2258,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 53,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2259,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 54,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2260,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 55,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2261,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 56,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2262,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 57,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2263,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 58,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2264,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 59,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2265,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 60,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2266,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 61,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2267,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 62,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2268,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 63,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2269,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 64,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2270,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 65,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2271,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 66,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2272,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 67,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2273,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 68,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2274,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 69,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2275,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 70,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2276,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 71,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2277,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 72,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2278,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.truqap"
    ],
    "proposition_id": 718,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.truqap:0"
  },
  {
    "id": 2279,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tukysa"
    ],
    "proposition_id": 425,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tukysa:0"
  },
  {
    "id": 2280,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.tykerb"
    ],
    "proposition_id": 195,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.tykerb:0"
  },
  {
    "id": 2281,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.vectibix"
    ],
    "proposition_id": 692,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.vectibix:1"
  },
  {
    "id": 2282,
    "type": "Statement",
    "description": "",
    "contributions": [
      0,
      3
    ],
    "reportedIn": [
      "doc:hc.verzenio"
    ],
    "proposition_id": 0,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.verzenio:0"
  },
  {
    "id": 2283,
    "type": "Statement",
    "description": "",
    "contributions": [
      0,
      3
    ],
    "reportedIn": [
      "doc:hc.verzenio"
    ],
    "proposition_id": 1,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.verzenio:0"
  },
  {
    "id": 2284,
    "type": "Statement",
    "description": "",
    "contributions": [
      0,
      3
    ],
    "reportedIn": [
      "doc:hc.verzenio"
    ],
    "proposition_id": 2,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.verzenio:0"
  },
  {
    "id": 2285,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.verzenio"
    ],
    "proposition_id": 792,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.verzenio:1"
  },
  {
    "id": 2286,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.verzenio"
    ],
    "proposition_id": 793,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.verzenio:1"
  },
  {
    "id": 2287,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.verzenio"
    ],
    "proposition_id": 794,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.verzenio:1"
  },
  {
    "id": 2288,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.verzenio"
    ],
    "proposition_id": 12,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.verzenio:1"
  },
  {
    "id": 2289,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.verzenio"
    ],
    "proposition_id": 13,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.verzenio:1"
  },
  {
    "id": 2290,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.verzenio"
    ],
    "proposition_id": 14,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.verzenio:1"
  },
  {
    "id": 2291,
    "type": "Statement",
    "description": "",
    "contributions": [
      0,
      5
    ],
    "reportedIn": [
      "doc:hc.vitrakvi"
    ],
    "proposition_id": 199,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.vitrakvi:0"
  },
  {
    "id": 2292,
    "type": "Statement",
    "description": "",
    "contributions": [
      0,
      5
    ],
    "reportedIn": [
      "doc:hc.vitrakvi"
    ],
    "proposition_id": 200,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.vitrakvi:0"
  },
  {
    "id": 2293,
    "type": "Statement",
    "description": "",
    "contributions": [
      0,
      5
    ],
    "reportedIn": [
      "doc:hc.vitrakvi"
    ],
    "proposition_id": 201,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.vitrakvi:0"
  },
  {
    "id": 2294,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 479,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2295,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 480,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2296,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 481,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2297,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 482,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2298,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 483,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2299,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 484,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2300,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 485,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2301,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 486,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2302,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 487,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2303,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 488,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2304,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 489,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2305,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 490,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2306,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 491,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2307,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 492,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2308,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 493,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2309,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 494,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2310,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 495,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2311,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 496,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2312,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 497,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2313,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.voranigo"
    ],
    "proposition_id": 498,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.voranigo:0"
  },
  {
    "id": 2314,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.vyloy"
    ],
    "proposition_id": 514,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.vyloy:0"
  },
  {
    "id": 2315,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.xalkori"
    ],
    "proposition_id": 84,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.xalkori:0"
  },
  {
    "id": 2316,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.xalkori"
    ],
    "proposition_id": 85,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.xalkori:1"
  },
  {
    "id": 2317,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.xospata"
    ],
    "proposition_id": 709,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.xospata:0"
  },
  {
    "id": 2318,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.xospata"
    ],
    "proposition_id": 710,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.xospata:0"
  },
  {
    "id": 2319,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.xospata"
    ],
    "proposition_id": 152,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.xospata:0"
  },
  {
    "id": 2320,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.xospata"
    ],
    "proposition_id": 153,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.xospata:0"
  },
  {
    "id": 2321,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.xospata"
    ],
    "proposition_id": 154,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.xospata:0"
  },
  {
    "id": 2322,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.xospata"
    ],
    "proposition_id": 155,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.xospata:0"
  },
  {
    "id": 2323,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.xospata"
    ],
    "proposition_id": 156,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.xospata:0"
  },
  {
    "id": 2324,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.xospata"
    ],
    "proposition_id": 157,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.xospata:0"
  },
  {
    "id": 2325,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.yervoy"
    ],
    "proposition_id": 171,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.yervoy:0"
  },
  {
    "id": 2326,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.yervoy"
    ],
    "proposition_id": 173,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.yervoy:1"
  },
  {
    "id": 2327,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.yervoy"
    ],
    "proposition_id": 642,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.yervoy:3"
  },
  {
    "id": 2328,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.zelboraf"
    ],
    "proposition_id": 426,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.zelboraf:0"
  },
  {
    "id": 2329,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.zelboraf"
    ],
    "proposition_id": 711,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.zelboraf:0"
  },
  {
    "id": 2330,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.zykadia"
    ],
    "proposition_id": 77,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.zykadia:0"
  },
  {
    "id": 2331,
    "type": "Statement",
    "description": "",
    "contributions": [
      0
    ],
    "reportedIn": [
      "doc:hc.zykadia"
    ],
    "proposition_id": 77,
    "direction": "supports",
    "strength_id": 0,
    "indication_id": "ind:hc.zykadia:1"
  }
]
